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INTRODUCTION [1] 
 
Solid medicaments may be administered orally as powders, pills, cachets, capsules or tablets. 
These dosage forms contain a quantity of drug which is given as a single unit and they are known 
collectively as solid unit dosage forms, even in the case of sustained action preparations which, 
technically, contain the equivalent of several normal doses of drug  .The stringent  formulation  
requirements  of  modern   medicaments,  the  many advantages of tablet and capsule medication, 
coupled with expanding health services and the commitment need for large-scale economic 
manufacture, have led to a steady decline in the prescribing of powders and pills. Tablets and capsules, 
on the other hand, currently account for well over two third of the total number and cost of medicines 
produced all over the world. 
 
ORAL DRUG DELIVERY [ 2,3 ] 
This is the most widely utilized route of administration among all the routes that have been 
explored for systemic delivery of drugs via pharmaceutical products of different dosage form. Oral 
route is considered most natural, uncomplicated, convenient and safe due to its ease of administration, 
patient acceptance and cost effective manufacturing process 
Oral drug delivery is the most desirable and preferred method of administering and 
pharmacodynamics profiles with an acceptable level of safety to the patient.therapeutic agents for their 
systemic effects. In addition, the oral medication is generally considered as the first avenue investigated 
in the discovery and development of new drug entities, pharmaceutical formulations, mainly because of 
patient compliance and convenience in administration. Oral route of drug administration have wide 
acceptance up to 50-60% of total dosage forms. Solid dosage forms are popular because of ease of 
administration, accurate dosage, self-medication, pain avoidance and most importantly patient 
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compliance. The most popular solid dosage forms are tablets and capsules. But the important drawback 
of these dosage forms is the difficulty to swallow 
 
Current technologies in oral drug delivery  
Over the last 3 decades, many novel oral drug therapeutic systems have been invented along with 
the appreciable development of drug delivery technology. Although these advanced DDS are 
manufactured or fabricated in traditional pharmaceutical formulations, such as Tablets, Capsules, 
Sachets, Suspensions, Emulsions, and Solutions, they are superior to the conventional oral dosage 
forms in terms of their therapeutic efficacies, toxicities, and stabilities. Based on the desired therapeutic 
objectives, oral DDS may be assorted into three categories:  
• Immediate-release preparations,  
• Controlled-release preparations and        
• Targeted- release preparations.  
 
Immediate-Release Preparations [4] 
These preparations are primarily intended to achieve faster onset of action for drugs such as analgesics, 
antipyretics, and coronary vasodilators. Other advantages include enhanced oral bioavailability through 
transmucosal delivery and pregastricabsorption, Convenience in drug administration to dysphasic patients, 
especially the elderly and bedridden.Conventional IR formulations include fast disintegrating tablets and 
granules that use effervescent mixtures, such as sodium carbonate (or sodium bicarbonate) and citric acid 
(or tartaric acid), and superdisintegrants, such as sodium starch glycolate, crosscarmellose sodium, and 
crospovidone. Current technologies in fast-dispersing dosage forms include modified tableting systems, 
floss or Shear form technology, which employs application of centrifugal force and controlled temperature, 
and freeze-drying.  
Super disintegrants in immediate release [5]: 
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These are especially important for an immediate release product where rapid release of dug 
substance is required. A disintegrant can be added to powder blend for direct compression.              
Table-1 list of Super Disintegrants 
 
 
 
 
                   
 
 
 
 
 
 
 
 
Mechanism of tablet disintegration [5]: 
Disintegrants , an important excipient of the tablet formulation, are always added to tablet to induce 
breakup of tablet when it comes in contact with aqueous fluid and this process of disintegration of 
constituent particles before the drug dissolution occurs, is known as disintegration process and 
excipients which induce this process are known as disintegrants. 
The tablet breaks to primary particles by one or more of the mechanisms: 
• Capillary action (wicking) 
• Swelling 
Super disintegrants Example Mechanism of action Special comment 
Crosscarmellose 
 
Crosslinked 
Cellulose 
-Swells 4-8 folds in < 10 
seconds. 
-Swelling and wicking both. 
-Swells in two 
dimensions. 
-Direct compression or 
granulation 
Crospovidone 
 
Crosslinked 
PVP 
-Swells very little and returns to 
original size after compression 
but act by capillary action 
-Water insoluble and 
spongy in nature so get 
porous tablet 
Pre Gelatinized Starch Starch 1500 
-Swells 7-12 folds 
in < 30 seconds 
-Swells in three 
dimensions and high 
level serve as sustain 
release matrix 
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• Due to deformation 
• Due to release of gases 
Capillary action (Wicking): 
Effective disintegrants that do not swell are believed to impart their disintegrating action through 
porosity and capillary action. Tablet porosity provides way for the penetration of fluid into tablets. The 
disintegrant particles (with cohesiveness and compressibility) themselves act to enhance porosity and 
provide these capillaries into the tablet. Liquid is drawn up or leak into these ways by capillary action 
and rupture the inter-particulate bonds causing the tablet to break into small particles 
Swelling: 
 
Not all disintegrants swell in contact with water swelling is believed to be a mechanism in which; 
certain disintegrating agents (like starch) impart their disintegrating effect. By swelling on contact with 
water the adhesiveness of other ingredients in a tablet is overcome causing the tablet to disintegrate. 
 
Deformation: 
Starch grains are generally thought to be “elastic” in nature that is the grains that are deformed 
under pressure will return to their original shape when that pressure is removed. But, with the 
compression force involved in tableting, these grains are permanently deformed and are said to be 
“Energy Rich” with these energy being released upon exposure to water, i.e. the ability for starch to 
swell is higher in “Energy Rich starch” grains than in starch grains that have not been deformed under 
pressure. It is believed that no single mechanism is responsible for the action of most disintegrants. But 
rather, it is more likely the result of inter-relationships between these major mechanisms 
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 Release of gases  
Carbon dioxide released within tablets on wetting due to interaction between bicarbonate and 
carbonate with citric acid or tartaric acid. The tablet disintegrates due to generation of pressure within 
the tablet. This effervescent mixture is used when we needs to formulate very rapidly dissolving tablets 
or fast disintegrating tablet. 
Controlled-Release Preparations (CR) 
The currently employed CR technologies for oral drug delivery are diffusion-controlled systems; 
solvent activated systems, and chemically controlled systems. Diffusion-controlled systems include 
monolithic and reservoir devices in which diffusion of the drug is the rate-limiting step, respectively, 
through a polymer matrix or a polymeric membrane. Solvent-activated systems may be either 
osmotically controlled or controlled by polymer swelling. Chemically controlled systems release drugs 
via polymeric degradation (surface or bulk matrix erosion) or cleavage of drug from a polymer chain. It 
is worth mentioning here that the so-called programmed-release (‘‘tailored-release’’) profile of a final 
CR product is rarely the outcome of a single pharmaceutical principle. Depending on the specific 
physicochemical properties of the drug in question and desired therapeutic objectives, different 
formulation and CR principles may be proportionally combined within the same dosage form. This task 
appears to be simpler when realized in terms of appropriate selection of polymers and excipients that 
incorporate desired principles. 
 
Targeted-Release Preparations 
Site-specific oral drug delivery requires spatial placement of a drug delivery device at a desired site 
within the gastro Intestinal (GI) tract. Although it is virtually possible to localize a device within each 
part of GI tract, the attainment of site-specific delivery in the oral cavity and the rectum is relatively 
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easier than in the stomach and the small and large intestines. The latter requires consideration of both 
longitudinal and transverse aspects of GI constraints. 
 
TABLETS [2, 3, 6] 
Tablet is defined as a compressed solid dosage form containing medicaments with or without 
excipients. According to the Indian Pharmacopoeia Pharmaceutical tablets are solid, flat or biconvex 
dishes, unit dosage form, prepared by compressing a drug or a mixture of drugs, with or without 
diluents. They vary in shape and differ greatly in size and weight, depending on amount of medicinal 
substances and the intended mode of administration. It is the most popular dosage form and 70% of the 
total medicines are dispensed in the form of Tablet. All medicaments are available in the Tablet form 
except where it is difficult to formulate or administer. 
 
 
Advantages of the Tablet dosage form are: 
1. They are unit dosage form and offer the greatest capabilities of all oral dosage form for the 
greatest dose precision and the least content variability. 
2. Cost is lowest of all oral dosage form. 
3. Lighter and compact. 
4. Easiest and cheapest to package and strip. 
5. Easy to swallowing with least tendency for hang-up. 
6. Delayed release product is possible by enteric coating. 
7. Objectionable odour and bitter taste can be masked by coating technique. 
8. Suitable for large scale production. 
9. Greatest chemical and microbial stability over all oral dosage form. 
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10. Product  identification  is  easy  and  rapid  requiring  no  additional  steps  when employing 
an embossed and/or monogrammed punch face. 
 
Disadvantages of Tablet dosage form are: 
1. Difficult to swallow in case of children and unconscious patients. 
2. Some drugs resist compression into dense compacts, owing to amorphous nature, low density 
character. 
3. Drugs with poor wetting, slow dissolution properties, optimum absorption high in GIT may be 
difficult to formulate or manufacture as a tablet that will still provide adequate or full drug 
bioavailability. 
4. Bitter testing drugs, drugs with an objectionable odor or drugs that are sensitive to oxygen may 
require encapsulation or coating. In such cases, capsule may offer the best and lowest cost. 
General properties of Tablet dosage forms: 
 
1. A tablet should have elegant product identity while free of defects like chips, cracks, discoloration, 
and contamination. 
2. Should  have  sufficient  strength  to  withstand  mechanical  shock  during  its production 
packaging, shipping and dispensing. 
3. Should have the chemical and physical stability to maintain its physical attributes over time. 
4. The tablet must be able to release the medicinal agents in a predictable and reproducible manner. 
5. Must have a chemical stability over time so as not to follow alteration of the medicinal agents. 
Different types of Tablets: 
(A) Tablets ingested orally: 
 
1. Compressed tablet, e.g. Paracetamol tablet 
2. Multiple compressed tablet 
3. Repeat action tablet 
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4. Delayed release tablet, e.g. Enteric coated Bisacodyl tablet 
5. Sugar coated tablet, e.g. Multivitamin tablet 
6. Film coated tablet, e.g. Metronidazole tablet 
7. Chewable tablet, eg: antacid tablet 
 
(B) Tablets used in oral cavity: 
 
1. Buccal tablet, 
2. Sublingual tablet, 
3. Troches or lozenges 
4. Dental cone 
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 Fig:1, Flow chart for types of tablets: 
 
 
 
TYPES OF TABLETS
ORAL TABLETS FOR 
INGESTION
Multiple  
Compressed Tablets
Compression Coated Tablet
Layered Tablet
Inlay Tablet
Standard compressed Tablets
Modified Release Tablet
Delayed action Tablet
Targeted Tablet
Chewable Tablet
Dispersible Tablet
TABLETS USED IN THE ORAL 
CAVITY
Lozenges and 
Troches
Sublingual Tablet
1Sublingual tablet
Buccal Tablet
Dental Cones
Mouth dissolved Tablet
TABLETS ADMINISTERED 
BY OTHER ROUTES
Vaginal Tablet
Implants
TABLETS USED 
TO PREPARE 
SOLUTION
Effervescent Tablet
Hypodermic Tablet
Soluble Tablet
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 A.TABLETS INGESTED ORALLY 
1. Compressed tablets 
These tablets are uncoated and made by compression of granules. These tablets are usually intended 
to provide rapid disintegration and drug release. These tablets contain water-soluble drugs, which after 
swallowing get disintegrated in the stomach, and its drug contents are absorbed in the gastrointestinal 
tract and distribute in the whole body e.g. Paracetamol tablet 
2. Multiple compressed tablets: 
These tablets are prepared to separate physically or chemically incompatible ingredients or to 
produce repeat action prolonged action products. 
For incompatible components these are: 
A) Layered tablet- either two layered (for two components) or three layered (for three components) 
tablet. 
B) Compressed coated type- either tablet within a tablet or tablet within a tablet within a tablet. Tablet 
in this category are usually prepared for two reasons 
1. To separate physically or chemically incompatible ingredients. 
2. To produce repeat action or prolong action product. 
 
3. Multilayered tablets 
These tablets consist of two or more layer of materials compressed successively in the same tablets. 
The color of each layer may be the same or different. The tablets having layers of different colours are 
known as "multicoloured tablets". 
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4. Enteric-coated tablets 
These are compressed tablets meant for administration by swallowing and are designed to bypass 
the stomach and get disintegrated in the intestine only. These tablets are made to release the drug 
undiluted and in the highest concentration possible within the intestine. Eg: tablets containing 
anthelmentics, and amoebiacid. 
 
5.Sugar coated tablets 
The compressed tablets which have   an   sugar coating are called " sugar coated tablets”. Primary 
role of sugar coating is to produce an glossy, elegant tablets .these are used for preparing multivitamin 
tablets and minerals combination . , e.g. Multivitamin tablet 
6. Film coated tablets 
One  type of coated tablet in which drug is not required in coating .polymers such as hydroxyl 
propylmethyl cellulose,hydroxy propyl cellulose,collidol dispersion of cellulose are commonly used. 
advantages of film coat than sugar coat is better mechanical strength, flexibility and little increase in 
tablet weight. Application of thin polymer based coatings to tablet/granules by a spray atomization 
technique. Thickness of such coating is usually between 20-100 µm . eg. Metronidazole tablet 
7. Chewable tablets 
These tablets are chewed in the mouth and broken into small pieces. In this way, the disintegration 
time is reduced and the rate of absorption of the medicament is increased.  
e.g: aluminium hydroxide tablets, and phenolphthalein tablets. 
B.TABLETS USED IN ORAL CAVITY 
1. Sublingual tablets 
These tablets are to be placed under the tongue where they dissolve or disintegrate quickly and are 
absorbed directly without passing into GIT.  
Eg: tablets of glyceryl trinities 
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 2. Buccal tablets 
These tablets are to be placed in the buccal pouch or between the gums and lips or cheek where   
they dissolve or disintegrate slowly and are absorbed directly without passing into the alimentary canal. 
Eg: tablets of ethisterone 
3. Lozenge and torches  
These tablets are designed to external local effect in the mouth or throat. These tablets are 
commonly used to treat sore throat or to control coughing in common cold. They may contain local 
anaesthetics antiseptic, antibacterial agents, astringent and antitussives.  
C.TABLETS USED TO PREPARE SOLUTION  
1. Effervescent tablets: 
 Tablets are designed to produce a solution rapidly with the release of carbondioxide.the tablets are 
prepared by compressing the active ingredient with mixture of organic acid such as citric acid and 
sodium bi carbonate 
2. Hypodermic tablets: 
These tablets are composed of one or more drugs with water soluble ingredients. Drug is added to 
sterile water to prepare sterile solution, which Is inject able. 
 
3. Dispensing tablets: 
These tablets provide a convenient quality of potent drug that can be incorporated readily in to 
powders and liquids, thus circumventing the necessity to weigh small quantities. These tablets are, 
supplied primarily as a convenience for extemporaneous compounding and should never be dispensed 
as a dosage form. 
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 D. Tablets administered by other route  
1. Dental cones 
These are relatively minor compressed tablets meant for placing them in the empty socket-after 
tooth extraction. They prevent the multiplication of bacteria in the socket following such extraction by 
using slow releasing antibacterial compounds or to reduce bleeding by containing the astringent. These 
cones generally get dissolved in 20 to 40 min time. 
 2. Implantation tablets 
These tablets are placed under the skin or inserted subcutaneous by means of minor surgical 
operation and are slowly absorbed. These implants must be sterile and should be packed individually in 
sterile condition. Implants are mainly used for administration of hormones such as testosterone, and 
deoxycorticosterone etc. 
 
3. Vaginal tablets 
These tablets are meant to dissolve slowly in the vaginal cavity. These tablets are typically ovoid or 
pear shaped to facilitate retention in the vagina. This tablet form is used to release steroids, 
antibacterial agents, antiseptics or astringents to treat vaginal infections. 
The goal of any drug delivery system is to provide a therapeutic amount of drug in the proper site in 
the body to achieve promptly and then to maintain the desired   drug concentration that is, the drug 
delivery system should delivery system should deliver drug at a rate dedicated by the needs of the 
body over a specified period of treatment 
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MANUFACTURING METHODS [ 6,7 ] 
There are four general methods of tablet preparation. 
• Direct compression                                                                                                                             
• Wet granulation method 
• Dry granulation method 
• Fluidized bed granulation 
In the tablet-pressing process, it is important that all ingredients be dry, powdered, and of uniform 
grain size as much as possible. The main guideline in manufacture is to ensure that the appropriate 
amount of active ingredient is equal in each tablet so ingredients should be well-mixed. Compressed 
tablets are exerted to great pressure in order to compact the material. If a sufficiently homogenous mix 
of the components cannot be obtained with simple mixing, the ingredients must be granulated prior to 
compression to assure an even distribution of the active compound in the final tablet. Two basic 
techniques are used to prepare powders for granulation into a tablet: wet granulation and dry 
granulation.Powders that can be mixed well do not require granulation and can be compressed into 
tablets through Direct Compression.  
A. Direct Compression: 
This method is used when a group of ingredients can be blended and placed in a tablet press to make a 
tablet without any of the ingredients having to be changed. This is not very common because many 
tablets have active pharmaceutical ingredients which will not allow for direct compression due to their 
concentration or the excipients used in formulation are not conducive to direct compression.Granulation 
is the process of collecting particles together by creating bonds between them. There are several 
different methods of granulation. The most popular, which is used by over 70% of formulation in tablet 
manufacture is wet granulation. Dry granulation is another method used to form granules. 
Commonly used direct compression diluent are: microcrystallinecellulose , lactose, mannitol etc., 
Page | 28  
 
Steps involved in direct compression: 
Raw material  weighing  screening  mixing  compression  
The ideal requirements of excipients used in direct compression and its advantages, limitations 
Table: 2 Ideal Requirements,Advantages and Limitation of Direct compression   
Ideal requirements Advantages Limitations 
 
Flow ability 
 
Cost effectiveness production 
 
Segregation 
 
Compressibility 
 
Better stability of drug 
 
Variation in functionality 
 
Diluent pontential 
 
Faster dissolution 
 
Low dissolution potential 
 
Stability 
 
Simplified validation 
 
Poor compressibility 
 
Controlled particle size 
 
Less microbial contamination 
 
Lubricant sensitivity 
 
 
 
 
B. Wet Granulation: 
wet granulation is a process of using a liquid binder or adhesive to the powder mixture. The amount 
of liquid can be properly managed, and over wetting will cause the granules to be too hard and under 
wetting will cause them to be too soft and friable. Aqueous solutions have the advantage of being safer 
to deal with than solvents. 
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• Procedure of Wet Granulation  
• Step 1: Weighing and Blending - the active ingredient, filler, disintegration agents, are weighed and 
mixed. 
• Step 2: The wet granulate is prepared by adding the liquid binder/adhesive. Examples of 
binders/adhesives include aqueous preparations of cornstarch, natural gums such as acacia and 
cellulose derivatives such as methyl cellulose, CMC, gelatin, and povidone. Ingredients are placed 
within a granulator which helps ensure correct density of the composition. 
• Step 3: Screening the damp mass into pellets or granules 
• Step 4: Drying the granulation 
• Step 5: Dry screening: After the granules are dried, pass through a screen of smaller size than the 
one used for the wet mass to select granules of uniform size to allow even fill in the die cavity 
• Step 6: Lubrication- A dry lubricant, antiadherent and glidant are added to the granules either by 
dusting over the spread-out granules or by blending with the granules. Its reduces friction between the 
tablet and the walls of the die cavity. Antiadherent reduces sticking of the tablet to the die and punch. 
• Step7: liquid binder, but sometimes many actives are not compatible with water. Water mixed into 
the powder can form bonds between powder particles that are strong enough to lock them in together. 
However, once the water dries, the powders may fall apart and therefore might not be strong enough to 
create and hold a bond. 
C. Dry Granulation: 
This process is used when the product needed to be granulated may be sensitive to moisture and 
heat. Dry granulation can be conducted on a press using slugging tooling or on a roller compactor 
commonly referred to as a chilsonator. Dry granulation equipment offers a wide range of pressure and 
roll types to attain proper densification. However, the process may require repeated compaction steps to 
attain the proper granule end point. It requires drugs or excipients with cohesive properties. 
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• Some granular chemicals are suitable for direct compression (free flowing) e.g. potassium chloride. 
• Tableting excipients with good flow characteristics and compressibility allow for direct 
compression of a variety of drugs. 
D. Fluidized bed granulation: 
      It is a multiple step process performed in the same vessel to pre-heat, granulate and dry the 
powders. It is today a commonly used method in pharmaceuticals because it allows the individual 
company to more fully controls the powder preparation process. It requires only one piece of machinery 
that mixes all the powders and granules on a bed of air. 
 
EXCIPIENTS USED IN TABLETS FORMULATION:[8] 
Excipients are inert substances used as diluents or vehicles for a drug. In the pharmaceutical 
industry it is a catch all terms which includes various sub- groups. Comprising diluents or fillers, 
binders or adhesives, disintegrants, lubricants, glidants or flavours, fragrances and sweeteners. 
Selection of excepients as follows:- 
• They must be physiological inert. 
• They must be acceptable to regulatory agencies 
• They must be physiologically and chemically stable. 
• They must be free of any bacteria considered to be pathogenic or otherwise    objectionable. 
• They must be not interfering with the bioavailability of the drug. 
• They must be commercially available in the form and purity commensurate to pharmaceutical 
standards. 
• Cost must be relatively inexpensive. 
To assure that no excipient interferences with the utilization of the drug, the formulator must 
carefully and critically evaluate combinations of the drug with each of the contemplated excipients and 
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must ascertain compliance of each ingredient with existing standards and regulations.The screening of 
drug-excipients and excipient-excipient interactions should be carried out routinely in preformulations 
studies 
A. Lubricants: 
Lubricants are used   to ease the ejection of the tablet from the die, to prevent sticking of tablets to 
the punches, to prevent excessive wear on punches and dies. They function by interposing a film of low 
shear strength at the interface between the tablet and the die wall and the punch face.         
In selecting a lubricant, the following should be considered: 
• Lubricants markedly reduce the bonding properties of many excipients.  
• Over blending is one of the main causes of lubrication problems. Lubricants should be added last to 
the granulation and tumble-blended for not more than 10 min. 
• Lubricant efficiency is a function of particle size; therefore, the finest grade available should be 
used and screened through a 100-300 mesh screen before use. 
B. Fillers (Diluents): 
In order to facilitate tablet handling during manufacture and to achieve targeted content uniformity, 
the tablet size should be kept above 2-3 mm and weight of tablet above 50 mg. Many potent drugs have 
low dose (for e.g. Diazepam, Clonidine hydrochloride). In such cases diluents provide the required bulk 
of the tablet when the drug dosage itself is inadequate to produce tablets of adequate weight and size. 
Usually the range of diluent may vary from 5-80%. Diluents are also synonymously known as “fillers”. 
Diluents are often added to tablet formulations for secondary reasons like to provide better tablet 
properties such as: 
i. To provide improved cohesion 
ii.To allow direct compression manufacturing 
iii. To enhance flow 
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iv. To adjust weight of tablet as per die capacity 
 
C. Disintegrants: 
Disintegrants are used in tablet preparation to break the tablet faster. But some of the disintegrants 
are also having property of enhancing solubility of insoluble drug. 
Examples 
• Crospovidone: Crospovidone is disintegrant, crospovidone also enhances solubility. 
• Sodium starch glycollate: sodium starch glycollate is widely used in oral pharmaceuticals and as a 
disintegrant in capsule. 
 
 
D.Glidants : 
Glidants are materials that improve the flow characteristics of granules by reducing the inter particulate 
friction. In proper amounts they also serve to assure smooth and uniform flow at all times. Many of the 
excipients commonly used in tablet formulations are especially applicable for use in chewable tablets 
due to their ability to provide the necessary properties of sweetness and chewabilty. In general; these 
fall into the sugar category, although a combination of excipients with artificial sweeteners may 
provide a satisfactory alternative. 
EVALUATION OF THE PHARMACEUTICAL POWDERS: 
a) Bulk Density: 
It is the ratio of total mass of powder to the bulk volume of powder. It was measured by pouring the 
weighed powder into a measuring cylinder and initial weight was noted. This initial volume is called 
the bulk volume. From this the bulk density was calculated according to the formula mentioned below. 
It is expressed in g/ml and is given by 
Bulk density (BD) = Weight of the powder/ Volume of powder 
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   BD      = W/V0   g/mL 
Weighed quantity of the powder (W) was taken in a graduated measuring cylinder and volume (V0) was 
measured and bulk density was calculated using the formula. 
b) Tapped Density: 
It is the ratio of weight of the powder to the tapped volume of powder. The powder was introduced 
into a measuring cylinder with the aid of funnel and tapped for 500 times using Tap Density tester USP 
I and the volume attained is the tapped volume. It is expressed in g/ml and is given by 
 
 Tapped density (ρt) = M/Vf 
Weighed quantity of powder was taken in a graduated cylinder and the volume was measured (V0). The 
graduated cylinder was fixed in the ‘Tapped Densiometer’ and tapped for 500, 750 and 1250 times until 
the difference in the volume after consecutive tappings was less than 2%.  The final reading was 
denoted by (Vf). The volume of blend was used to calculate the tapped density, Hausner’s ratio and 
Carr’s Index. 
c) Angle of Repose  
The flow properties were characterized in terms of angle of repose, Carr’s index and Hausner’s 
ratio. For determination of angle of repose , the drug and the blend were poured through the walls of a 
funnel, which was fixed at a position such that its lower tip was at a height of exactly 2.0 cm above 
hard surface. The drug and the blends were poured till the time when upper tip of the pile surface 
touched the lower tip of the funnel. 
Angle of repose was calculated using following equation. 
Angle of Repose (θ) = tan-1(h/r) 
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Where, h = height of pile in cm, r = radius of pile in cm., θ = angle of repose 
Table: 3 angle of repose limits 
Angle of Repose Flow property 
<25 
25-30 
30-40 
>40 
Excellent 
Good 
Passable 
Very Poor 
 
 
d)Carr’s index: 
Carr’s index is also known as compressibility. It is indirectly related to the relative flow rate, 
cohesiveness and particle size. It is simple, fast and popular method of predicting powder flow 
characteristics. 
Table: 4 Carr’s index and corresponding flow properties 
Carr’s Index (%) Flow 
5-15 
16-18 
18-21 
23-35 
33-38 
>40 
Excellent 
Good 
Fair to passable 
Poor 
Very poor 
Very very poor 
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 Carr’s index was calculated by using the formula: 
 Carr’s Index   =  (Tapped Density –Bulk Density) x   100        
                      Tapped Density 
e) Hausner’s ratio: 
    Hausner ratio indicates the flow properties of the powder and measured by the ratio of tapped density 
to bulk density. The relationship between Hauser’s ratio and flow property. 
               
                            
   Table:5 Hausner’s  ratio and corresponding flow properties 
Hausner’s Ratio Property 
0-1.2 Free flowing 
1.2-1.6 Cohesive Powder 
     
 Hausner ratio was calculated by using the formula. 
 Hausner Ratio   =  Tapped density / Bulk density 
 Hausner Ratio = Vf/V0  
 Where V0   = Initial volume      
   V f  = Final volume 
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 EVALUATION OF TABLETS [9,10, 11]: 
 Physical appearance: 
        The general appearance of the tablet,its identity and general elegance is essential for consumer 
acceptance, for control of lot-to- lot uniformity and tablet to tablet uniformity.the control of general 
appearance involves the measurement of size,shape,colour,presence, or absence of odour, taste etc. 
Weight variation test: 
Twenty (20) tablets from each batch were individually weighed. The average weight and standard 
deviation were calculated, individual weight of each tablet was also calculated using the same and 
compared with average weight .Weight Variation limits as per USP and the values were showed in the 
table-30. 
Table: 6 Weight Variation that has be presented Solid dosage form 
Average weight in mg % ± deviation allowed 
130 or less 10 
130-324                         7.5 
More than 324 5 
The content uniformity approach is preferred over the weight variation approach as it more precisely 
reflects the variation of the active ingredient from tablet to tablet. 
The required specification for this test is that uniformity of dosage unit should be within a range of 
85%–115% with a relative standard deviation of less than or equal to 6%. 
Friability: 
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This test is intended to determine, under defined conditions, the friability of uncoated tablets, the 
phenomenon whereby tablet surfaces are damaged and/or show evidence of lamination or breakage 
when subjected to mechanical shock or attrition. Commercially available apparatus known as 
“friabilators” are used for the test. Basically, it consists of a drum with diameter between 283mm and 
291mm and having width of 36 mm–40 mm, made of transparent plastic material. The drum is attached 
to the horizontal axis of a device that rotates at 25±1 rpm. The tablets are tumbled at each turn of the 
drum by a curve projection with an inside radius of 75.5 mm–85.5mm that extends from middle of the 
drum to outer wall. Thus, at each turn, the tablets roll or slide and fall onto the drum wall or onto each 
other. Usually, a sample of 10 tablets are tested at a time, unless tablet weight is 0.65 g or less, where 
20 tablets are tested. After 100 turns, the tablet samples are evaluated by weighing. If the reduction in 
the total mass of the tablets is more than 1%, the tablets fail the friability test.  
Generally, the test is done once. If cracked, cleaved, or broken tablets are obvious, then the sample 
also fails the test.  
Thickness: 
The thickness in millimeters (mm) was measured individually for 10 pre weighed tablets by using a 
Vernier Caliper’s. The average thickness and standard deviation were reported in table- 
Hardness testing: 
          A tablet requires a certain amount of mechanical strength to withstand the shocks of handling in its 
manufacturing, packing, shipping and dispensing. As discussed before, hardness and friability are most 
common measures used to evaluate tablet strength. If a tablet is more fragile than expected, then the 
friability test will detect its substandard quality. If the tablets are more robust than desired, then tablet 
hardness test that will detect the deficiency. The most widely used apparatus to measure tablet hardness is 
the Schleuniger apparatus. This, and other newer electrically operated test equipment, eliminates the 
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operator variability inherent in the measurement using older apparatuses. Generally, the force required to 
break a tablet may be expressed in either kilograms or pounds.  
Disintegration test [5]: 
A disintegration test is a test to establish how fast a tablet disintegrates into aggregates and/or finer 
particle, the test is conducted using a specially designed instrument known as disintegration apparatus. The 
apparatus employs a basket of six tubes with a base of metal sieve. A tablet is placed in each tube and is 
held in place by a plastic weight. The six-tube assembly, containing six tablets, is suspended using a hanger 
with a mechanism of vertical motion at a fixed speed of 28- 32 cycles/minute. While hanging the six-tube 
assembly on the hanger, the assembly is moved in vertical motion in water or a buffer solution. The time 
for disintegration of each tablet is recorded and should meet the required time specification.Table: 7   The 
Pharmacopoeial specifications for disintegration testing 
 
Tablet Type 
 
 
Time limit and Specifications 
 
BP 
Uncoated             <15min 
Coated Film <30min 
Sugar <60min, repeat in 0.1MHCl 
Gastro resistant, enteric >120min in 0.1MHCl 
<60min in pH 6.8(Phosphate) 
 
Effervescent <5min in 200mL, water, 20°C 
Soluble <3min 
Dispersible <3min, 2 tablets in 100mL water dispersed, USP 
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Uncoated <15min 
Plain coated <30 min 
Enteric coated Intact for 60min in simulated gastric fluid, disintegrated in 
simulated intestinal fluid<monograph time 
Buccal <4hours 
 
 
Assay: 
  This test is a quantitative version of the identification test. Again, 10–20 tablets are ground and the active 
ingredient is dissolved or extracted in a suitable solvent using the standard procedure. The concentration of 
the extracted solution is determined using a specific and validated spectroscopic or chromatographic 
method against a solution of reference standard. These results are reported as percent of expected/labeled 
value. Although the specifications for assay results differ from product to product, generally the expected 
range for individual active ingredient is to be within 90%–110% of the labeled amount.  
Dissolution [12,13 ]: 
                   Dissolution is the process by which a solid solute enters a solution. In the pharmaceutical industry, 
it may be defined as the amount of drug substance that goes into solution per unit time under standardized 
conditions of liquid/solid interface, temperature and solvent composition. 
Dissolution is considered as one of the most important quality control tests performed on   
pharmaceutical dosage forms and is now developing into a tool for predicting bioavailability, and in some 
cases, replacing clinical studies to determine bioequivalence. 
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Dissolution behaviour of drugs has a significant effect on their pharmacological activity. In fact, a 
direct relationship between in- vitro dissolution rate of many drugs and their in-vivo bioavailability has 
been demonstrated and is generally referred to as in-vitro in-vivo correlation, IVIVC. 
 
 
 
Dissolution Testing Conditions: 
Apparatus: 
The most commonly employed dissolution test methods are  
The basket method (Apparatus 1) and  
The paddle method (Apparatus 2)  
     The basket and the paddle methods are simple, robust, well standardized and used worldwide. These 
methods are flexible enough to allow dissolution testing for a variety of drug products. Apparatus 1 and 
Apparatus 2 should be used unless shown to be unsatisfactory. The in-vitro dissolution procedures, such as 
the reciprocating cylinder (Apparatus 3) and a flow-through cell system (Apparatus 4) described in the 
USP may be considered, if needed. These methodologies or other alternatives/modifications should be 
considered on the basis of their proven superiority for a particular product. Because of the diversity of 
biological and formulation variables and the evolving nature of understanding in this area, different 
experimental modifications may need to be carried out to obtain a suitable in-vivo correlation with in-vitro 
release data. Dissolution methodologies and apparatus described in the USP can generally be used either 
with manual sampling or with automated procedures. 
Dissolution Medium: 
Dissolution testing should be carried out under physiological conditions, if possible. This allows 
interpretation of dissolution data with regard to in-vivo performance of the product. However, strict 
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adherence to the gastrointestinal environment need not be used in routine dissolution testing. The testing 
conditions should be based on physicochemical characteristics of the drug substance and the environmental 
conditions the dosage form might be exposed to after oral administration. 
 
The volume of the dissolution medium is generally 500, 900, or 1000 mL. Sink conditions are 
desirable but not mandatory. An aqueous medium with pH range 1.2 to 6.8 (ionic strength of buffers is 
given in USP) should be used.  
 
To simulate intestinal fluid (SIF), a dissolution medium of pH 6.8 should be employed. A higher pH 
should be justified on a case-by-case basis and, in general, should not exceed pH 8.0.  
 
To simulate gastric fluid (SGF), a dissolution medium of pH 1.2 should be employed without 
enzymes. The need for enzymes in SGF and SIF should be evaluated on a case-by-case basis and should 
be justified. Recent experience with elatin capsule products indicates the possible need for enzymes 
(pepsin with SGF and pancreatin with SIF) to dissolve pellicles, if formed, to permit the dissolution of the 
drug. Use of water as a dissolution medium also is discouraged because test conditions such as pH and 
surface tension can vary depending on the source of water and may change during the dissolution test 
itself, due to the influence of the active and inactive ingredients. For water insoluble or sparingly water 
soluble drug products, use of a surfactant such as sodium lauryl sulfate is recommended. The need for and 
the amount of the surfactant should be justified. Use of a hydro alcoholic medium is discouraged.  
 
All dissolution tests for IR dosage forms should be conducted at 37±0.5°C. The basket and paddle 
method can be used for performing dissolution tests under multimedia conditions (e.g., the initial 
dissolution test can be carried out at pH 1.2, and, after a suitable time interval, a small amount of buffer can 
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be added to raise pH to 6.8). Alternatively, if addition of an enzyme is desired, it can be added after initial 
studies (without enzymes).  
 
             Use of Apparatus 3 allows easy change of the medium. Apparatus 4 can also be adopted 
     for a change in dissolution medium during the dissolution run.  Certain drug products and     
    formulations are sensitive to dissolved air in the dissolution medium and may need deaeration 
 
PROBLEMS IN TABLET MANUFACTURING [2] 
             An ideal tablet should be free from any functional defect or visual defect. Functional defects are due 
to faulty formulation. Visual defect are either related to imperfections in any one or more of the following 
factors: 
• Tableting Process 
• Excipient 
• Machine  
The problems in manufacturing and their remedies are 
A. Capping: 
Definition: 
‘            Capping’ is the term used, when the upper or lower segment of the tablet separates horizontally, 
either partially or completely from the main body of a tablet and comes off as a cap, during ejection from 
the tablet press, or during subsequent handling. 
Reason:  
Capping is usually due to the air–entrapment in a compact during compression and subsequent 
expansion of tablet on ejection of a tablet from a die. 
Remedies: 
Page | 43  
 
 1. Remove some fines through 100 or 200 mesh. 
2. Moisten the granules suitably. Add hygroscopic substance e.g.: sorbitol, methyl- cellulose  
3.Increasing the amount of binder or Adding dry binder such as pre-gelatinized starch, gum acacia, 
powdered sorbitol, PVP, hydrophilic silica or powdered sugar. 
4.Polish dies properly. Investigate other steels or other materials. 
5.I Make proper setting of lower punch during ejection ncrease the amount of lubricant or change the type 
of lubricant. 
B. Lamination:  
Definition:  
       ‘Lamination’ is the separation of a tablet into two or more distinct horizontal layers. 
Reason:  
      Air-entrapment  during compression and subsequent release on ejection. The condition is exaggerated 
by higher speed of turret Use flat punches. 
REMEDIES: 
•Use a less amount of lubricant or change the type of lubricant e.g.: Magnesium-stearate. 
•Use tapered dies, i.e. upper part of the die bore has an outward taper of 3° to 5°. 
C. Chipping: 
Definition: 
            ‘Chipping’ is defined as the breaking of tablet edges, while the tablet leaves the press or during 
subsequent handling and coating operations. 
Reason:  
Incorrect machine settings, specially mis-set ejection take-off. 
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Remedies: 
• Dry the granules properly or increase lubrication 
• Moisten the granules to plasticize. Add hygroscopic substances 
• Polish to open end, reverse or replace the die 
D. Sticking / Filming: 
Definition:  
‘Sticking’ refers to the tablet material adhering to the die wall. 
‘Filming’ is a slow form of sticking and is largely due to excess moisture in the     granulation. 
Reason:  
Improperly dried or improperly lubricated granules 
Remedies: 
• Dry the granules properly. Make moisture analysis to determine limits 
• Increase or change lubricant 
• Increase pressure in machine 
• Reduce speed 
E. Binding: 
Definition:  
‘Binding’ in the die, is the term used when the tablets adhere, seize or tear in the die. A film is 
formed in the die and ejection of tablet is hindered. With excessive binding, the tablet sides are cracked 
and it may crumble apart. 
Reason:  
Binding is usually due to excessive amount of moisture in granules, lack of lubrication and/or use of 
worn dies. 
Remedies: 
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• Dry the granules proper 
• Increase the amount of lubricant or use a more effective lubricant 
• Reduce granular size, add more fines, and increase the quantity of lubricant. 
• If coarse granules, reduce its size. Use wear-resistant dies. 
F. Mottling: 
Definition:  
          ‘Mottling’ is the term used to describe an unequal distribution of colour on a tablet, with light or dark 
spots standing out in an otherwise uniform surface. 
Reason:  
One cause of mottling may be a coloured drug, whose colour differs from the colour of excipients used 
for granulation of a tablet. 
Remedies: 
• Change the solvent system, Change the binder, Reduce drying temperature 
• Incorporate dry colour additive during powder blending step, then add fine powdered adhesives such as 
acacia and tragacanth and mix well and finally add granulating liquid in case of improper mixing of 
colour. 
G. Double impression: 
Definition:  
‘Double Impression’ involves only those punches, which have a monogram or other engraving on 
them. 
Remedies: 
•Use keying in tooling, i.e. inset a key alongside of the    punch, so that it fits the punch and prevents 
punch rotation.  
•Newer presses have anti-turning devices, which prevent punch rotation 
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TABLET COATING [14,15 ]: 
Coating has an several functions .it strengthen the tablets,improve taste,colour,make easy to handle, 
package and control the release of tablets. all drug have thir own characterstics for example bitter in 
taste ,unpleasant odour, some are sensitive to light, hygroscopic, which are all can be  altered by 
coating . 
Tablet film coating is performed by two types: 
One is aqueous fim coating generally water is used as an solvent and another is non aqueous film 
coating where non  organic solvent is used.high quality of aqueous fim coating must be smooth, 
uniform, and adhere satisfactorily to the tablet surface and should be stable to drug. 
Reason for tablet coating 
A number of reasons can be suggested:  
• The core contains a material which has a bitter taste in the mouth or has an unpleasant odour.  
• Coating will protect the drug from the surroundings with a view to improve its stability.  
• Coating will increase the ease by which a tablet can be ingested by the patient.  
 
• Coating will develop the mechanical integrity; means coated products are more resistant to 
mishandling (abrasion, attrition etc.)  
• The core contains a substance which is incompatible in the presence of light and  
• Subject to atmospheric oxidation, i.e. A coating is added to improve stability.  
• The core alone is inelegant.  
• The active substance is coloured and migrates easily to stain hands and clothes.  
• The coated tablets are packed on high-speed packaging machine. Coating reduces  
• Friction and increases packaging rate.  
• Coating can modify the drug release profile, e.g., enteric coating, osmotic pump,  
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• pulsatile delivery. 
 
Types of coating  
• Sugar coating 
• Film coating 
• Enteric coating  
• Controlled release coating 
• Specialized coating 
• Compressed coating 
• Electrostatic coating 
• Dip coating 
• Vacuum film coating 
1. FILM COATING: 
Film coating is the process whereby a tablet, capsule, or pellet is surrounded by a thin layer of 
polymeric material. Film coated tablets are compressed tablets with a thin layer of suitable polymer 
capable of forming a skin like film over the tablet. The polymeric substance most commonly used are 
hydroxyl propyl methyl cellulose, hydroxyl methyl cellulose, The film is usually colored and has the 
advantage over sugar coating in that it is more durable, less bulky, and less time consuming to apply. 
The film coating protects the medicament from the atmospheric effects. By its composition the coating 
is designed to rupture & expose the core tablet at the desired location within GIT. 
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Table-8 Reasons for Film coating 
Reasons for film coating include 
Appearance To change the color, for branding purposes or other aesthetic reasons 
Stability 
To protect the active ingredient from moisture, light, and/or the acidic 
environment of the stomach 
Taste/odor  Masking To provide an easy to swallow tablet without the bitter taste of many actives 
Release characteristics 
Many film coating materials have functional properties which enable the 
delayed (enteric) release of dosage forms 
 
Film coating materials: 
Usually spray process is employed in preparation of film coated tablet. Accelacota is the type of 
prototype of perforated cylindrical drum providing drying air capacity. Fluidized bed equipment has 
made considerable impact where tablets are moving in a stream of air passing through the perforated 
bottom of a cylindrical column with a smaller cylindrical insert the stream of cores is rising in the 
centre of device together with spray mist applied in the middle of the bottom. For fluidized coating very 
hard tablet hardness above 20 N have to be used 
 
Components required for film coating formulations: 
1. Polymer: 
        Usually cellulose deraivatives , acrylic and copolymers are used 
Non enteric polymers: 
               Eg: hypermellose , hydoxyethyl cellulose, polyethylene glycol,ethylcellulose, 
hydroxyl propyl cellulose. 
Enteric polymers: 
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 Cellulose  acetate phthalate, polymethaacrylates, polyvinyl acetate phthalate. 
2. Plasticizers: 
Plasticizer are low molecular weight materials, which have tendency to alter physical properties of 
the polymer to render it more useful in function as film coating materil.it is of 3 types-Polyos type 
which contain glycerol,propylene glycol,polyethylene glycol, organic esters contain phthalate esters, 
dibutyl acetate, citrate esters. oils/glycerides contain castor oil, monoglycerides, coconut oil. 
3. Solvents: 
Its main function is to dissolve polymers and other additives.some of solvents are., 
• Water 
• Alcohols 
• Ketones 
• Esters 
• Chlorinated hydrocarbon 
Among this water is a common solvent of choice, due to environmental and economic 
considerations. 
4. colourants/opaquants: 
These are the common materials used in film coating as an ingredient to contribute the visual appeal of 
the product. 
Colorants can be classified into 3 classes: 
Organic dyes example: Sunset yellow, tartrazine, erythrosine  
Inorganic colours example: iron oxide red ,yellow, titanium dioxide,talc. 
Natural colours example: riboflavin, carmine. 
MISCELLANEOUS: 
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To provide dosage form with a single chractestic,special materials used to incorporate      into a 
solution. 
Flavors: 
Flavors are added to tablet formulation in order to make them enough in case of chewable tablet by 
improving the taste. Flavours are commonly used to improve the taste of chewable tablets as well as 
mouth dissolved tablets. Flavours are incorporated either as solids (spray dried flavours) or oils or 
aqueous (water soluble) flavors. 
Sweeteners: 
Sweeteners are added to tablet formulation to improve the taste of chewable tablets. Sweeteners 
used in tablet formulation- Mannitol, Lactose, Sucrose, Dextrose, Saccharin, Cyclamate, Aspartame etc 
Antioxidants: 
Antioxidants are added in tablet formulation to protect drug from undergoing oxidation. 
Antioxidants undergo oxidation in place of drug or they block the oxidation reaction or they act as 
synergisys to other antioxidants. 
Adsorbents: 
Adsorbents are the agents that can retain large quantities of liquids. Therefore liquids like Vitamin 
E can be incorporated into tablets by addition of adsorbents. Most commonly used adsorbents in 
pharmaceuticals are anhydrous calicium phosphate, starch, magnesium carbonate, bentonite, kaoline, 
magnesium oxide. Generally the liquid to be adsorbed is first mixed with the adsorbent prior to 
incorporation into the formulation. 
 
Wetting Agents: 
Wetting Agents in tablet formulation aid water uptake and thereby enhancing disintegration and 
assisting in drug dissolution. Incorporation of anionic surfactant like Sodium Lauryl Sulphate (SLS) is 
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known to enchance the dissolution. It has been established that SLS improves permeation of drug 
biological membrane since it destroys the path through which drug has to pass and thus minimizing the 
path length for the drug to travel. Wetting agents are mainly added when hydrophobic drug is to be 
formulated into tablet. SLS, Sodium disobutylsulfosuccinate are used as wetting agent in tablet 
formulation 
Coating process [15]: 
Film coating of tablets is a multivariate processes,with many different factors,such as coating 
equipement, coating liquid, and processes parameters which affect the pharmaceutical quality of the 
final product. many film former have different chemical nature and different   characterstics. percentage 
solid content present in coating liquid may affect tablet surface and coating efficacy. Processes 
parameters such as spray rate, atomizing air pressure, inlet air temperature, rotating speed of the fan 
influences coating. optimization of above parameters result in formation of a proper film, whereas 
improper spraying or aleterd airpressure, temperature, fan speed result in sticking of film, reduced 
tablet porosity, breakage. 
Film Coatings for Every Application : 
         Colorcon offers a wide range of film coating products, many of which can be formulated 
specifically for your application and regulatory requirements. Whether the desired function for your 
tablet or particulate is immediate release, delayed (enteric) release and/or extended (controlled) release, 
the tablet film coating technology needed to enhance, protect, and modify the functionality of  product. 
Immediate Release 
A distinctive product appearance offers many benefits to the producers and marketers of 
pharmaceutical tablets and nutritional supplements. Film coating is the most economical method of 
enhancing your product – improving visual appearance, as well as easing swallow ability, and 
enhancing the taste and masking objectionable odors. Colorcon film coatings can impart mechanical 
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integrity, color, gloss, pearlescence or moisture protection to create an immediate release tablet that is 
both memorable and effective. 
Extended Release  
The extensively used polymer for extended release coating was Ethyl cellulose. 
Application of an ethyl cellulose film from aqueous dispersion or organic solution provides the 
formulator the means to control the release of drug from a tablet or multiparticulatevia diffusion of the 
drug through the ethyl cellulose film. Novel means of controlled release can also be achieved using a 
combination of Colorcon's modified release coating systems. 
 
Delayed Release 
The enteric/delayed release products can help the deliver of final product that saves you 
development, scale-up and production time while assuring the integrity of the coating for the safety and 
efficacy of your finished dosage form. Various systems are available based on a variety of delayed 
release polymers for aqueous or organic processing to provide targeted release at various pH 
conditions.  
For the solid dosage manufacturer, tablet film coating technology conveys many benefits including 
improved packaging efficiency, prevention of cross contamination and reduced tablet breakage and 
chipping. A large variety of pigmented and non-pigmented tablet film coating systems available. Which 
is cost Effective, protect from light moisture and environmental gases. 
Immediate Release Film Coating Systems for Tablets [15,16,17] 
Colorcon, the innovator and industry standard for complete film coating systems, offers a range of 
custom pigmented and non-pigmented film coatings for immediate release solid dose applications. film 
coating  formulas produce attractive, elegant coatings on even the most challenging tablet surfaces and 
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can be used in both aqueous and organic coating procedures.An extensive selection of polymer blend 
formulations provides the user with the ability to impart . 
Benefits include: 
• Reduced coating process time  
• Superior adhesion on difficult to coat cores  
• Less stressful processing conditions for heat sensitive, friable or high drug   
   Content cores 
• Sharper logo definition, even at higher weight gains  
• Better gloss and smoothness compared to conventional film coatings  
• Improvedcolor stability. 
Aqueous film coating is the quickest and least expensive method for enhancing your tablet 
appearance and, unlike other methods, will not affect dissolution or disintegration profiles. dry-blend 
systems consist of polymers, plasticizers and pigments, combined in one, easy-to-use, dry powder 
system which is rehydrated quickly and simply with water. Colorcon also offers customized colour 
selection and colour matching of our immediate release tablet film coating products.  
 
Celeron’s ongoing research of film coating polymers has produced many enhanced polymer 
combinations resulting in new tablet coating options for our customers. Our newly developed, dry 
coating technology provides benefits such as improved adhesion, reduced processing times, and 
application of the tablet coating at wider process parameters. Advances in our immediate release tablet 
film coating technology not only give a more elegant appearance to your solid oral dosage form, but 
provide unique. 
Stability studies: 
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The purpose of at ability testing is to provide evidence of quality of the drug substance or drug 
product ,and how it varies with time under the influence of a variety of environmental condition(heat, 
humidity, light ,air)the final formlation was packed  in suitable packing like blister and strip packs and 
then they will be kept at different temperature, humidity conditions and the samples will be analyzes of 
their physical and chemical properties. 
Table: 9  ICH guidelines for stability study. 
 
      study 
 
Storage conditions 
 
Time period 
 
Long term 
250c+20c/60%RH+5% RH 
or 
300c+20c/65% RH+5%RH 
12 month 
 
intermediate 
 
300C/65%RH +5%+RH 
6 month 
 
accelerated 
 
400C+20C/75%RH+5%RH 
6month 
 
 
HYPERTENSION [18,19,20 ] 
Introduction:  
High blood pressure, also called hypertension, is elevated pressure of the blood in the arteries. 
Hypertension results from two major factors, which can be present independently or together: 
•The heart pumps blood with excessive force. 
•The body's smaller blood vessels (known as the arterioles) narrow, so that blood flow exerts more 
pressure against the vessels' walls. 
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Blood pressure is the force applied against the walls of the arteries as the heart pumps blood 
through the body. The pressure is determined by the force and amount of blood pumped and the size 
and flexibility of the arteries. 
Two numbers are used to describe blood pressure: the systolic pressure (the higher and first 
number) and the diastolic pressure(the lower and second number). Health dangers from blood pressure 
may vary among different age groups and depending on whether systolic or diastolic pressure (or both) 
is elevated. A third measurement, pulse pressure, may also be important as an indicator of severity. 
Systolic Blood Pressure.  
The systolic pressure (the first and higher number) is the force that blood exerts on the artery walls 
as the heart contracts to pump out the blood. High systolic pressure is now known to be a greater risk 
factor than diastolic pressure for brain, heart, kidney, and circulatory complications and for death, 
particularly in middle-aged and elderly adults. The wider the  spread between the systolic and diastolic 
measurements, the greater the danger. 
 
 
Diastolic Blood Pressure.  
The diastolic pressure (the second and lower number) is the measurement of force as the heart 
relaxes to allow the blood to flow into the heart. High diastolic pressure is a strong predictor of heart 
attack and stroke in young adults .There are a number of ways to categorize or describe hypertension. 
Essential Hypertension. Essential hypertension is also known as primary or idiopathic hypertension. 
About 90% of all high blood pressure cases are this type. The causes of essential hypertension are 
unknown but are based on complex processes in all major organs and systems, including the heart, blood 
vessels, nerves, hormones, and the kidneys. 
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            Secondary Hypertension. Secondary hypertension comprises about 5% of high blood pressure cases. In 
this condition, the cause has been identified. 
Blood Pressure Guidelines 
           Blood pressure is measured in millimeters of mercury (mm Hg). According to current adult 
guidelines, blood pressure is categorized as normal, prehypertensive, and hypertensive (which is further 
divided into Stage 1 and 2, according to severity). 
• Normal blood pressure is below 120/80 mm Hg. 
• High blood pressure is greater than or equal to 140 mm Hg (systolic) or greater than or 
equal to 90 mm Hg (diastolic). 
          Blood pressure readings in the prehypertension category (120 -139 systolic or 80 - 89 diastolic) 
indicate an increased risk for developing hypertension. 
 Hypertension is defined as average systolic and diastolic readings that are greater than the 95th 
percentile for gender, age, and height on at least three occasions. 
Pre-hypertension in children is diagnosed when average systolic or diastolic blood pressure levels 
are at least in the 90th percentile but less than the 95th percentile. For adolescents, as with adults, blood 
pressure readings greater than 120/80 are considered prehypertensive. Increasing rates of childhood 
obesity have led to increasing rates of hypertension and pre-hypertension among children and 
adolescents. Although more children are having high blood pressure, recent studies indicate that 
pediatric hypertension is frequently under diagnosed.   
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 Table-10 ,blood pressure ranges 
Blood Pressure Ranges 
Blood Pressure 
Category 
Ranges for Most Adults (systolic/diastolic) 
Normal Blood 
Pressure 
(systolic/diastolic) 
Systolic below 120 mm Hg 
Diastolic below 80 mm Hg  
Pre hypertension Systolic 120 - 139 mm Hg 
Diastolic 80 - 89 mm Hg 
(NOTE: 139/89 or below should be the minimum goal for everyone. 
People with heart disease, peripheral artery disease, diabetes or chronic 
kidney disease should strive for 130/80 or less.) 
Mild Hypertension 
(Stage 1) 
Systolic 140 - 159 mm Hg 
Diastolic 90 - 99 mm Hg 
Moderate-to-Severe 
Hypertension (Stage 
2) 
Systolic over 160 mm Hg or 
Diastolic over 100 mm Hg 
Causes for hypertension 
Blood pressure tends to rise as people get older and thus everyone’s risk for hypertension increases with 
age. Behavior and lifestyle-related factors can put people at a higher risk for developing high blood 
pressure. This includes eating too much salt (sodium), not eating enough potassium (from fruits and 
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vegetables), being overweight, not getting enough exercise, as well as drinking too much alcohol and 
smoking. 
About 60% of people who have diabetes also have high blood pressure. 
Symptoms of hypertension: 
High blood pressure is called the "silent killer" because it often has no warning signs or symptoms, 
and many people do not realize they have it; that is why it's important to get blood pressure checked 
regularly. Hypertension is usually without any symptoms, but could give rise to early-morning 
headache, nosebleed, irregular heartbeats and buzzing in the ears. Symptoms of severe hypertension 
include tiredness, nausea, vomiting, confusion, anxiety, chest pain and muscle tremors .The only way to 
detect high blood pressure is to have it measured by a doctor or a health professional. Measuring blood 
pressure is quick and painless. 
Adverse health effects of hypertension 
High blood pressure can cause serious damage to health. It can harden the arteries, decreasing the 
flow of blood and oxygen to the heart. This reduced flow can cause 
Chest pain, also called angina. heart failure, which occurs when the heart cannot pump enough 
blood and oxygen to other organs. heart attack, which occurs when the blood supply to the heart is 
blocked and heart muscle cells die from lack of oxygen. The longer the blood flow is blocked, the 
greater the damage to the heart.High blood pressure can burst or block arteries that supply blood and 
oxygen to the brain causing stroke. 
Prevent and control high blood pressure [21] 
High blood pressure is largely preventable by adopting lifestyle modifications at early stages. 
Treating hypertension is associated with a reduction in cardiovascular complications. Below is a list of 
actions to prevent hypertension.Reduce and manage mental stress through yoga, meditation and other 
relaxing techniques Eat a healthy diet consisting of lots of fresh fruits and vegetables, which provides 
Page | 59  
 
nutrients such as potassium and fiber.Limit intake of sodium by reducing the amount of salt added to 
food. The total daily intake of salt or sodium chloride from all sources should be no more than 5 gm per 
day (1 tea spoon). Be aware that many processed foods are high in sodium. Avoid or reduce “pickles”, 
“papads”, “chutneys” and soy sauces which are high in sodium.Limit the intake of food high in 
saturated fats. Eliminate/reduce transfats in diet.Maintain a healthy weight. Being overweight can raise 
blood pressure. Losing weight can help lower blood pressure.Be physically active. Physical activity can 
help lower blood pressure. Adults should engage in moderate physical activity for at least 30 minutes 
on most days of the week.Do not use tobacco. Smoking injures blood vessels and speeds up the 
hardening of arteries. Smoking is a major risk factor for heart disease and stroke. If not using tobacco, 
do not start. If already using tobacco, quitting will lower the risk for heart disease and stroke. 
Antihypertensive drugs [20,21]: 
ACE inhibitors: 
• Benazepril 
• Captopril   
• Enalapril     
• Fosinopril  
• Quinapril  
• MoexiprilARBs  
Angiotensin II receptor blocker: 
• Losartan  
• Valsartan  
• Irbesartan  
• Telmisartan  
• Olmesartan  
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• Candesartan  
• Eprosartan  
• Potassium-sparing diuretics  
• Amiloride  
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 LITERATURE REVIEW 
1. Kannan et al (2012)., Reported the  Development and Evaluation of Valsartan Film Coated Tablets 
The aim of the present study is to formulate and evaluate immediate release tablets of Valsartan. 
Preformulation studies were performed prior to compression. Tablets were formulated by direct 
compression, wet granulation and slugging techniques. The fabricated tablets were evaluated for 
various pre compressional parameters like angle of repose, bulk density, tapped density, 
compressibility index, Hausner's ratio and post compressional parameters like average weight, 
thickness, hardness, friability, assay, disintegration time and dissolution studies. Comparatively, 
slugging technique exhibited the good flow property than direct compression technique. The 
stability studies were carried out for the optimized batch for six months. The results of the present 
study showed that among all the formulations, F8 was better in all terms of pre compression and 
post compression parameters and showed comparably a good dissolution profile with that of the 
innovator product .[22,23] 
 
2. Richa Sood et al (2012)., Reported  Immediate Release Antihypertensive Valsartan oral tablet. 
Tablet is the most popular among all dosage forms existing today because of its convenience of self 
administration, compactness and easy manufacturing; however in many cases immediate onset of 
action is required than conventional therapy. To overcome these drawbacks, immediate release 
pharmaceutical dosage form has emerged as alternative oral dosage forms. There are novel types of 
dosage forms that act very quickly after adminstration.[24]  
 
3. Pradeeep kumar et al(2012)., aimed  to develop pharmaceutical equivalent ,suitably and quality 
improved formulation of film coated ticlopidine hydrochloride. Immediate release  tablet for direct 
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compression technique .the current study involves preparation and evaluation of ticlopidine 
hydrochloride .the three superdisintegrnts used.the study were crosscarmellose,microcrystalline 
cellulose and native starch.where these excipient combination shows good evaluations and best 
drug release.[25] 
4. Rajesh et al(2012)., develop a stable formulation of antibiotic drug clarithromycin as an 
immediate- release tablet. The task of developing immediate release tablet is accomplished by using 
suitable diluents and superdisintegrants. Faster disintegration of the tablet administrated orally 
minimizes absorption time and improves its bioavailability in less time. . The formulated tablets 
were evaluated for various precompression  parameters and post compression parameters like 
thickness, hardness, weight variation, friability, disintegration test, drug content uniformity and in 
vitro release studies. The formulation F8 showed satisfactory physical parameters, and it was found 
to be stable among other formulations. From this study, it was concluded that optimized 
clarithromycin tablet (OF7) containing croscarmellose sodium (3.029%) showed better 
characteristics of immediate release tablets[26]. 
5. SatyamPandey et al (2011)., Developed and characterized valsartan and hydrochlorothiazide film 
coated tablet , They are solid, flat or biconvex disc in shape. They vary greatly in shape, size and 
weight which depend upon amount of medicament used and mode of administration. They also vary 
in hardness, thickness, disintegration and dissolution characteristics and in other aspects depending 
upon their intended use and method of manufacture.[27]   
6. Nataraj et al (2011)., Simple precise accurate UV Spectroscopic method has been developed and 
validated for estimation of valsartan in pure and pharmaceutical dosage form. UV Spectroscopic 
method which is based on measurement of absorption of UV light, the spectra of valsartan in 
methanol showed maximum wave length at 250nm and calibration graphs were plotted over the 
concentrations ranging from 2-20μg/ml of valsartan with correlation coefficient 0.9968 validation 
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was performed as per ICH Q2 (R1) guidelines for linearity, accuracy, precision and recovery. The 
limit of detection (LOD) and limit of quantification (LOQ) were found to be 0.15 and 0.449 
respectively by simple UV Spectroscopy .The proposed method was validated.[28] 
7. Soumya et al (2011)., The purpose of the present investigation was to develop and optimize 
bilayered sustained release matrix tablets of Valsartan. The tablets contained an immediate 
releasing layer with the loading dose oThe drug polymer interaction was investigated by FTIR and 
DSC and their results directed further course of formulation. Valsartan tablets were evaluated for 
various post compression parameters like Tablet hardness, Friability, Weight variation, Drug 
content and In vitro dissolution. The results were found to be within the acceptable limits f the drug 
and a sustaining layer with maintenance dose of drug prepared by wet granulation method. The FT- 
IR Spectrum of pure valsartan drug was compared with the FT- IR spectrum of physical mixture of 
valsartan. The characteristic functional groups of the pure valsartan and physical mixtures of 
valsartan showed similar with minor changes [29] 
8. Srinivas et al (2010)., formulate and evaluate of Valsartan film coated tablets. In order to obtain 
the best optimized product, eight different formulations were developed using diluents, binder, 
glidant, lubricant, and different concentrations of superdisintegrant. Tablets were formulated by 
direct compression, slugging and wet granulation techniques. Various pre-compressional 
parameters like bulk density, tapped density, compressibility index and Hausner’s ratio and post 
compressional parameters like weight variation, thickness, hardness, friability, disintegration time, 
and drug release were studied. Comparatively granulation techniques exhibited the good powder 
flow than direct compression technique. Based on this investigation results, the drug release from 
tablets increased with increasing concentration of superdisintegrant. The formulation F-7 was 
showed good drug release and selected as an optimized formulation and it was concluded that 
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superdisintegrant concentration, granulation technique, binder, and lubricants plays a key role in the 
formulation development and optimizing the immediate release tablet of Valsartan formulation.[30] 
9. Nasiruddin Ahmad Farooqui et al (2010)., aimed to formulate film coated tablets of secnidazole 
by wet granulation and the granules are compressed for tablets and they are coated with polymers 
for getting film coated tablets at specified conditions and the evaluation of film coated tablets for 
the following parameters as description, average weight, weight variation, hardness test, thickness, 
dissolution, related substances, disintegration time and assay of tablet for compliance with 
acceptance criteria, for formulation of secnidazole film coated tablets.[31]  
10.  Abbaspour et al (2010)., concluded that Hydrolysis is the dominant process in degradation of 
drugs, especially for esteric compounds e.g. aspirin. There are several methods for moisture 
protection of drugs including reduction of drug solubility, modification of chemical structure, 
moisture-resistant packaging and coating of solid dosage forms. Specific polymer coatings are used 
to protect moisture sensitive drugs. The aim of this study is to design and evaluate a moisture-
resistant film formulation based on HPMC [32] 
11.  Bhatia M. Sudesh et al(2010)., Valsartan was subjected to different ICH prescribed stress studies. 
The stability-indicating assays were established by using isocratic RP-HPLC separation C18 
column (250 mm length×4.6 mm internal diameterand 5 μm particle size) for both major degradants 
of valsartan by acid hydrolysis and by oxidation. The mobile phase comprising of methanol: water 
(70:30v/v, pH 7.2) was used in acid hydrolysis stability-indicating assay and the mobile phase 
comprising of methanol:water (60:40v/v, pH 7.2) was used in oxidation stability-indicating assay of 
valsartan. A simple, precise, and accurate isocratic reversed-phase stability-indicating high 
performance liquid chromatographic assay method was developed and validated for determination 
of valsartan.[33] 
12. Jain  et al (2009)., Reported the formulation and evaluation of fast dissolving tablets of valsartan, 
In this investigation fast dissolving tablets of valsartan were prepared using different super 
disintegrants by direct compression method. FDTs were evaluated for physicochemical properties 
and in vitro dissolution. Effect of disintegrant on disintegration behaviour of tablet in artificial 
saliva, pH 5.8 was evaluated. Wetting time of formulations containing Crospovidone was least and 
tablets showed fastest disintegration.[34] 
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13. Agnivesh R shrivastava et al(2009)., reported the Solubility and dissolution rate of valsartan a 
poorly water soluble antihypertensive was enhanced  by preparation of solid dispersion granules 
which would additionally allow easy compression into tablets. The dispersion granules were 
prepared using a hot melt granulation technique which involved preparation of a homogenous 
dispersion of valsartan in gelucire-50/13 melt, followed by its adsorption on to the surface of 
aeroperl-300pharma®, an inert adsorbent. A two-factor, three-level (32) statistical design was 
implemented to quantitate the influence of gelucire-50/13 and aeroperl-300pharma on the 
dissolution profile and flow properties of the dispersion granules, where gelucire-50/13 and 
aeroperl-300pharma® were chosen as independent variables, while dissolution and flow properties 
were chosen as dependent variables. The dispersion granules were characterized for their in-vitro 
dissolution rate and flow properties. An appropriate statistical model was arrived at and a 
significantly enhanced dissolution rate and flow properties were exhibited with the optimized 
formulation.[35] 
14.  Navin Sheth et al (2009)., studied the aqueous-based film coating of tablets utilizing a laboratory 
scale side-vented perforated pan-coating apparatus. The process parameters of potential importance 
with respect to the final film quality were evaluated by using trial and error method. Tablets were 
evaluated for coating uniformity (mg), coating process efficiency (%), surface roughness, and 
%LOD (loss on drying). Spray rate and inlet air temperature both affect the all characteristic of 
coated tablets. Rotating speed of pan mainly affect the coating uniformity of tablets. % Solid 
content affects the surface of coated tablets and also creates a problem in spray flow. The process 
parameters relevant to a side vented perforated pan coating process can be identified and, 
consequently, optimized.[36] 
 
15.  Praveen et al(2008)., Oral controlled release matrix tablet formulations of isoniazid using 
hydroxylpropyl methylcellulose (HPMC) as a hydrophilic release retardant polymer and to study 
the influence of various formulation factors like proportion of the polymer, polymer viscosity 
grade, compression force, and release media on the in-vitro release characteristics of the drug. 
Finally the release rate of drug was highly influenced by above characters  [37] 
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16.  Saishravan et al (2008) .,reported the formulation and evaluation of valsartan film coated tablets. 
The present work was aimed at the formulation development and evaluation of Valsartan film 
coated tablets.  Valsartan is used for the treatment of Hypertension and is an angiotensin II receptor 
blocker. Immediate release drug delivery is desired for drugs having long biological half life and 
poor bioavailability. Valsartan tablets are formulated as immediate release dosage forms. The 
tablets were formulated using direct compression, dry granulation and wet granulation techniques. 
In order to obtain the best optimized formula eight different formulations were developed using 
different binders, super disintegrants, diluents and glidants.  The formulated tablets were evaluated 
for various tableting properties, like hardness, thickness, friability, weight variation, disintegration 
time and dissolution rate. Evaluating the results,it was determined that the drug release from the 
tablet was increased as the concentration of superdisintegrant was increased and the F8 formulation 
showed a good release pattern.[38] 
17. Bhalekar et al(2008).,Hydrophilic polymer (HPMC) and hydrophobic polymer (Ethyl cellulose) 
based Nicorandil matrix sustained release tablet which can release the drug up to 24 hrs in 
predetermined rate. The in-vitro release rate profile should be higher concentration Gaur gum 
polymer in tablet, the combination of hydrophilic and hydrophobic combination showed less result 
than use of alone.[39] 
 
18. Setty et al(2008).,prepared aceclofenac fast dispersible tablets by direct compression method using 
superdisntegrants crosscarmellose,sodium starch glycolate and crospovidone and their effect on 
wetting time. disintegration ,dissolution shows best due to increased amount of sodium starch 
glycolate than  crosscarmellose.[40] 
 
 
19. Babu et al(2007)., prepared solid dispersions of piroxicam in five superdisintegrants are namely., 
microcrystalline cellulose,crosspovidone,crosscarmellose sodium and with water soluble carriers of 
polyvinylpyrrolidine.solid dipersion gave good drug release due to addition of superdiaintegrants.[41] 
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20. Biraju patel et al(2001)., developed fast dissolving tablets of glipizide  by direct compression 
method with a view to enhance patient compliance. Two superdisintegrants viz, crospovidone and 
croscarmellose sodium (4%, 5%, 6%) with different binders viz, pvp k-30 and pregelatinized starch 
(3%) were used. The prepared batches of tablets were evaluated for hardness, friability, weight 
variation, disintegration, wetting time, drug content and in vitro dissolution studies. Based on 
evaluating parameters, Formulation prepared by using 5% croscarmellose sodium with 3% PVP 
K30 was selected as optimized formulation. Finally, the optimized formulation was compared with 
marketed conventional formulation. Stability studies were carried out at 25ºC / 60% RH and 40ºC / 
75% RH for optimized formulation for 2 months. Stability studies on the optimized formulation 
indicated that there was no significant change found in physical appearance, disintegration time and 
wetting time of the tablets.[42] 
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AIM AND OBJECTIVE 
 AIM: 
The aim of present work is to design and development of valsartan film coated tablets and its evaluation. 
 
Valsartan is an angiotensin II receptor antagonist and is widely used in the management of hypertension to 
reduce cardiovascular mortality in patients with left ventricular dysfunction following myocardial 
infarction, and in the management of heart failure. 
 
Valsartan is rapidly absorbed from the gastrointestinal tract after oral administration and can be 
administered without regard to food intake. The peak effect of valsartan is evident in 2–4 h; the 
bioavailability is 25%. Valsartan has a half- life of 6–9 h and demonstrates antihypertensive effects for 
approximately 24 h. Less than 10% of an orally administered dose of valsartan undergoes 
biotransformation in the liver; the enzymes responsible for its metabolism are unknown, and no active 
metabolites have been identified. 
 
The aim is to develop formulations of valsartan film coated tablet using different superdisintegrants 
(Croscarmellose, Crospovidone) by direct compression technique and the tablets were evaluated for 
various physiochemical properties. The effect of superdisintegrants on disintegration and dissolution of 
valsartan tablet were also studied extensively and compare with marketed  product. 
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The present study objectives are… 
• Preformulation studies: Compatability between drug and excipients 
• Evaluation of powder blends like bulk density, tapped density, hausner’s ratio, compressilbility 
index. 
• Preparation of valsartan tablet 
• Evaluation of tablets: thickness, disintegration, friability,hardness,  weight variation, assay.  
• Preparation of film  Coating  tablet 
• Evaluation of film coating tablets:thickness,disintegration,friability, hardness,assay. 
• In vitro dissolution studies 
• To determine the best fit dissolution profile with marketed product 
• Stability studies 
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PLAN OF WORK 
The scheme of the entire work is listed as follows: 
Active pharmaceutical ingredients characterization 
• Physical observation 
•  Solubility  
• Bulk density  
• Tapped density 
• Hausner’s Ratio 
• Compressibility  Index 
Preformulation studies 
• Compatibility studies between drug with various excipients 
Preparation and evaluation of powder blend.  
• Angle of repose 
• Bulk density and tapped density 
• Compressibility index 
• Hausner’s Ratio 
Preparation and evaluation of uncoated tablets 
• Tablet appearance 
• Hardness 
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• Weight Variation 
• Friability 
•  Thickness 
• Disintegration test 
• Assay 
Preparation and evaluation valsartan film coated tablets  
• Tablet appearance 
• Hardness 
• Friability 
• Thickness 
• Disintegration test 
• In vitro dissolution testing 
 Comparison of Invitro dissolution profile of optimized formulation with marketed product. 
Stability Studies. 
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DRUG AND EXCEPIENT PROFILE: 
VALSARTAN [43,44,45] 
Chemical formula          : C24H29N5O3 
 Molecular Weight         : 435.518 
Physical state                  : white or off white crystalline powder. 
Melting point                  : 116-1170c 
PHARMACOKINETIC DATA 
Bioavaibility                      : 25% 
Half life                              : 6-9 hours 
Excretion                            : renal-3, Biliary-70% 
 
Structural formula: 
 
 
IUPAC name: (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-
yl)phenyl]phenyl}methyl)pentanamido]butanoic acid 
Categories: Antihypertensive Agents, Angiotensin II Receptor Antagonists 
Dose: 40, 80, 160, 320 mg daily 
 
Page | 73  
 
Mechanism of action: 
Valsartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many 
tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated 
vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular 
resistance and blood pressure. Valsartan is selective for AT1 and has virtually no affinity for AT2. 
Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while 
decreasing potassium excretion. The primary metabolite of valsartan, valeryl 4-hydroxy valsartan, has no 
pharmacological activity. 
Metabolism: 
Valsartan is excreted largely as unchanged drug (80%) and is minimally metabolized in humans. The 
primary circulating metabolite, 4-OH-valsartan, is pharmacologically inactive and produced CYP2C9. 4-
OH-valsartan accounts for approximately 9% of the circulating dose of valsartan. Although valsartan is 
metabolized by CYP2C9, CYP-mediated  drug-drug interactions between valsartan and other drugs is 
unlikely. 
Side effect 
 •confusion, dizziness, light headedness or fainting spells 
•decreased amount of urine passed 
•difficulty breathing or swallowing, hoarseness, or tightening of the throat 
•fast or irregular heart beat, palpitations, or chest pain 
•skin rash, itching 
•swelling of your face, lips, tongue, hands, or feet 
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Description &Applications: 
Valsartan is an angiotensin II receptor blocker (ARB) that may be used to treat a variety of cardiac 
conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure 
by antagonizing the renin- angiotensin- aldosterone system (RAAS); it competes with angiotensin II for 
binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing 
effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the 
adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, 
left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the 
treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.It ia 
mainly used hypertension, it can be used in combination like with hydrochlorthiazide,or in bilayer with 
ammlodipine. 
Table: 11 Valsartan (80 mg) available in market: 
 
s. no 
 
Brand name 
 
manufacturer 
 
1 
 
Diovan (80mg) 
 
Novartis Indian ltd 
 
2 
 
Starval (80mg) 
 
Ranbaxy laboratories 
 
3 
 
Valent (80mg) 
 
Lupin laboratories ltd. 
 
5 
 
Valzaar (80mg) 
 
Torrent pharmaceuticals pvt ltd. 
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MANNITOL [46] 
Synonyms: Cordycepic acid, Manna sugar, D-mannite, Mannitolum, Mannogem. 
Chemical Name: D-Mannitol 
Empirical Formula:C6H14O6 
Structural formula 
 
 
 
 
Molecular Weight              : 182.17 
Functional Category      : Plasticizer, sweetening agent, tablet and capsule. 
Solubility: 
   Freely soluble in water, soluble in alkaline solutions, slightly soluble in pyridine, very slightly 
soluble in alcohol, practically insoluble in ether. 
Applications in Pharmaceutical Formulation or Technology 
 Mannitol is widely used as a diluent (10–90% w/w) and dissolution enhancer in tablet formulations, 
since it is not hygroscopic and may thus be used with moisture sensitive active ingredients. It may be 
used in direct compression tablet applications, for which the granular and spray dried forms are 
available, or in wet granulations. Granulations containing mannitol have the advantage of being dried 
easily. It is commonly used as an excipient in the manufacture of chewable tablet formulations and also 
used as a diluent in rapidly dispersing oral dosage forms.  
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Description 
      It occurs as a white, odourless, crystalline powder, or free flowing granules. It has a sweet taste and 
imparts a cooling sensation in the mouth. Microscopically, it appears as orthorhombic needles when 
crystallized from alcohol. 
Incompatibilities 
Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride or sodium 
chloride.(19) Precipitation has been reported to occur when a 25% w/v mannitol solution was allowed 
to contact plastic. Sodium cephapirin at 2 mg/mL and 30 mg/mL concentration is incompatible with 
20% w/v aqueous mannitol solution. Mannitol is incompatible with xylitol infusion and may form 
complexes with some metals such as aluminum, copper, and iron. Reducing sugar impurities in 
mannitol have been implicated in the oxidative degradation of a peptide in a lyophilized formation. 
Safety  
 Mannitol is a naturally occurring sugar alcohol found in animals and plants; it is present in small 
quantities in almost all vegetables. Laxative effects may occur if mannitol is consumed orally in large 
quantities. If it is used in foods as a bodying agent and daily ingestion of over 20 g is foreseeable, the 
product label should bear the statement ‘excessive consumption may have a laxative effect’. 
 
MAGNESIUM STEARATE [47,48] 
Structural formula      : 
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Non-proprietary name   : 
• BP                              :   magnesium stearate 
• JP                                :  magnesium stearate 
• PHEUR                       :  magnesiistearas 
• USP                             :  magnesium stearate 
 
Synonym                       : magnesium octadeconate, magnesium salt. 
Chemical name             : octadecanoic acid, magnesium salt 
Empirical formula        : C36H70O4 
Molecular weight          : 591.34 
Physical state:     
It is a fine,white, precipitated or milled, impalpable powder of   low bulk density, having a faint odour of 
stearic acid and a  characteristic taste  
Functional category:    tablet and capsule lubricant. 
Typical properties: 
• Density(bulk)          :     0.159 g/cm3 
• Density(tapped)      :    0.286 g/cm3 
• Density(true)           :    1.092 g/cm3 
• Melting point           :     117-150oc 
Solubility:      
Practically  insoluble in ethanol, ether, and water, slightly soluble in warm benzene and ethanol. 
 
Stability & storage:            
          Magnesium stearate is stable and should be stored in a well closed container in  a cool dry   place 
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 Incompatibilities:   
   It is incompatible with strong acids, alkalies, and iron salts. It cannot be used in products containing 
aspirin, vitamins and alkaloidal salts. 
Applications:     
 It is widely used in cosmetics, food products and   pharmaceutical formulations. It is used as a lubricant in 
capsule and tablet manufacture at concentration between 0.25-5.0  %. 
 
TALC [49] 
Synonyms                        : purified talc, talcum 
Empirical formula          : Mg3Si4O10(OH)2 
Molecular weight           :  379.266g/mol 
Physical state: 
 It is a very fine, white to greyish – white colored, odorless, impalpable, unctuous crystalline powder. It 
adheres readily to skin, is soft to the touch and free from grittiness 
Solubility:  
Practically  insoluble in dilute acids and alkalies, organic solvents, and water. 
Typical properties        : acidity/alkalinity: ph= 6.5-10 (20%w/v aqueous dispersion) 
Density                           : 2.7g/cm3 
Bulk density                  : 0.6 
Tapped density             :  1.1 
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Melting point               :  150˚c  
Stability and storage  : stored in a well-closed container in a cool and dry place. 
Incompatibility:  
Incompatible  with quaternary ammonium compounds. 
Application: 
Tablet and capsule diluents, anticakingagent, glidant, tablet and capsule lubricant. 
 It is widely used in oral dusting powder. Talc is additionally used to clarify liquids. 
 
MICROCRYSTALLINE CELLULOSE [50] 
Structural formula     : 
 
Nonproprietary name              
• BP          : microcrystalline cellulose 
• JP          :  microcrystalline cellulose 
• PHEUR : cellulosum microcrystallinum 
• USPNF: microcrystalline cellulose 
Synonym:avicel; cellulosegel; tabulose crystalline cellulose; e460; emcocel                                Fibrocel; 
vivace 
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Chemical name             :     cellulose 
 
Empirical formula        :    (C6H10O5)n  
Molecular   weight        :    246.98    
 
Functional category     : 
         Adsorbent; suspending agent; capsule and tablet diluents; tablet disintegrant.  
Physical state                  
      It is purified, partially depolymerised cellulose that occurs white odourless, tasteless, crystalline 
powder composed of porous particles. It is commercially available in different particle size and moisture 
grades which have different properties and applications. 
Typical properties      
 Density (bulk)            :        0.337 g/cm3 
  Density (tapped)        :        0.478 g/cm3 
  Density (true)            :        1.512-1.668 g/cm3 
 Melting point              :        chars at 260-270oc 
 Moisture content        :       less than 5% w/w 
Solubility: 
 Slightly soluble in 5%w/v sodium hydroxide solution, practically insoluble in water,    diluteacids, 
and most organic solvents. 
Stability & storage condition:            
         Microcrystalline     cellulose is a stable, though hygroscopic material. The bulk material should be 
stored in a well closed container in a cool, dry, place.  
 Incompatibilities:     
            Incompatible with   strong  oxidizing agents. 
    Applications:        
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   it is widely used in pharmaceuticals, primarily as a binder/ diluents in oral tablet and capsule 
formulations. where it is used in both wet granulation  and direct compression processes. 
Microcrystalline cellulose also has some lubricant and disintegrant properties that make it useful in 
tableting. It is also used in cosmetics and food products. 
 
CROSCARMELLOSE SODIUM [51] 
 Structural formula             
 
 
 
 
 
 
 
 
 
 
 
 Non-proprietary name:               
• BP   :   Croscarmellose sodium 
• USP  : Croscarmellose sodium 
 
Synonym               :  Ac-Di-Sol, Solute, Primellose, Pharmacel XL 
 
Chemical name    : Cellulose, carboxy methyl ether,  
 
Molecular weight :  90,000-7, 00,000. 
 
Physical state:     
 crosscarmellose sodium occurs as an odourless, white coloured powder. 
Functional category:  tablet and capsule disintegrant 
Typical properties: 
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• Density (bulk)                   : 0.529 g/cm3 
• Density (tapped)               : 0.819 g/cm3 
• Density (true)                    :      1.543 g/ 
Solubility:    
 Insoluble in water, rapidly swells to 4-8 times of  its original volume on contact with water. 
pH  :  the pH of a 1% w/v dispersion is 5.0 to 7.0 
 Stability & storage condition:    
       croscarmellose sodium is a stable though hygroscopic material. It should be stored     
In well closed container.,in cool dry place.   
Incompatibilities:  
  The efficacy of croscarmellosesodium, may be slightly  reduced in tablet formulations prepared by 
either wet  granulation or direct compression process which contains   hygroscopic excipients such 
as sorbitol. 
Applications:   
Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant for tablet, 
capsules and granules. In tablet formulations, croscarmellose sodium may be used in both direct 
compression and wet granulation processes.  
 
COLLOIDAL SILICON DIOXIDE [52] 
 
Nonproprietary Names: Colloidal Silicone Dioxide (Aerosil)  
BP: Colloidal anhydrous silica 
PHEUR: Silica colloidalis anhydrica 
USPNF: Colloidal silicon dioxide 
Synonyms: colloidal silica, fumed silica, light anhydrous silicic acid, silicic anhydride and silicon dioxide 
fumed 
Chemical Name: Silica 
Molecular Weight: 60.08 
 
 
Page | 83  
 
Structural Formula  
                                                  
Functional Category: 
          Adsorbent, anticakingagent, emulsion stabilizer, glident,  suspending agent, tabletdisintegrant, 
thermal stabilizer, and viscosity- 
increasing agent.  
Applications in Pharmaceutical Formulation or Technology  
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food products. Its small 
particle size and large specific surface area gives desirable flow characteristics that are exploited to 
improve the flow properties of dry powders in a number of processes such as tableting.  
Description: 
 Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of   about  15  nm.  It is a 
light, loose, bluish-white-colored, odorless, tasteless, and non-gritty amorphous powder.  
Stability and Storage Conditions: 
 Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water without 
liquefying. When used in aqueous systems at a pH 0-7.5, colloidal silicon dioxide is effective in 
increasing the viscosity of a system. However, at a pH greater than 7.5 the viscosity-increasing properties 
of colloidal silicon dioxide are reduced; and at a pH greater than 10.7 this ability is lost entirely since the 
silicon dioxide dissolves to form silicates. Colloidal silicon dioxide powder should be stored in a 
well-closed container. Some grades of colloidal silicon dioxide have hydrophobic surface treatments that 
greatly minimize their hygroscopicity.  
. 
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CROSPOVIDONE [53] 
Structural formula:  
 
Synonyms:crosslinkedpovidone,kollidoncl-m,polyplasdonexl,polyplasdonexl-10, 
polyvinylpolypyrolidone, PVP, 1-vinyl-2-pyrrolidinonehomopolymer. 
Non-proprietary names: 
 BP                     : crospovidone 
PHEUR             : crospovidonum 
USPNF              : crospovidone 
Chemical name : 1-ethenyl-2-pyrrolidinone homopolymer 
Empirical formula: (C6H9O)n 
Molecular weight  : >1000000 
Physical state:      
          crospovidone is a white to creamy-white, finely divided, free-flowing, practically   tasteless, 
odourless, hygroscopic powder. 
Solubility:  partially insoluble in water and most common organic solvents. 
   Bulk density                 :  0.323 g/cm3 
   Tapped density             : 0.461 g/cm3 
Acidity/alkalinity    : pH=5.0-8.0 
    Moisture content           : 60% 
Page | 85  
 
Application:                    
    crospovidone is a water- insoluble tablet disintegrate and dissolution agent use at 2-  5% 
concentration in tablet prepared by direct  compression or wet and dry granulation method. It is rapidly 
exhibits high capillary activity. Crospovidone can also be used as a solubility enhancer. With the 
techniques of co-evaporation, crospovidone can be used to enhance the solubility of poorly soluble 
drugs. The drug is absorbed on to crospovidone in the presence of a suitable solvent and the solvent is 
then evaporated. This technique results in faster dissolution rate. 
   Stability: it is a hygroscopic material. The bulk material 
   Storage: should be stored in a well- closed container in a cool, dry place. 
Incompatibilities:   
crospovidone is compatible with most organic and inorganic pharmaceutical ingredients. when 
exposed to a high water level, crospovidone may form molecular adduct with some materials. 
Handling precaution : handling with eye protection, gloves and dust mask 
Safety: it is widely used in oral pharmaceutical preparation and food products. 
 
Hydroxyl propl methyl cellulose [54,55] 
IUPAC name: hydroxyl propyl methyl cellulose 
Non-proprietory name 
IP          : hydroxy propyl methyl cellulose 
PHUR   : methylhydroxy propyl cellulosum 
BP         : hypromellose 
USP       : hypromellose 
Chemical name: cellulose,hydroxyl propyl methyl ether 
Synonyms: methyl hydroxyl propyl cellulose,propylene  glycol ether of methylcellulose. 
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 Structural formula: 
 
 
Physical and chemical properties: 
Molecular weight:    10,000-15,000 
Colour                 : white to creamy white 
Nature                 : granular powder 
Odor                    :  odorless 
Taste                    : tasteless 
Solubility: soluble in cold water,insoluble in chloroform,ethanol(95%) andether,but soluble in ethanol  
and dichloromethane mixture 
Melting point: browns at190-200,chars at225-230,glass transistion at170-180 
Functional category: 
Used as coating,film forming,rate controlling polymer for sustained release andtablet binder,suspending 
agent. 
Applications: 
Hpmc widely used in topical and oral fprmulation.in oral products hpmc is primarily used as tablet 
binder.conentration between 2-5%w/w  used as wet or dry granulation.hpmc used as adhesive in plastic 
bandages and as wetting agenr for hard contact lenses,it is widely used in cosmetics and food products. 
Safety: it is generally regarded as non toxic, nonirritant, so it is widely used in oral and topical 
pharmaceutical formulation. 
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 Lactose[56] 
 
IUPAC name:beta-d-galactopyranosyl-(1          4)-d-glucose 
Other name: milk sugar 
Structural name: 
 
 
Molecular formula : C12H22O11 
Density                     : 1.525 g/cm3 
Appearance             : white solid 
Melting point           : 202.80c 
Boiling point             : 668.90c 
Colour                       : white or off white crystalline powder 
Odour                         : odourless. 
Application and safety: 
Its bland flavor has lent to its use as a carrier and stabiliser of aromas and pharmaceutical products. Lactose 
is not added directly too many foods, because it is not sweet and its solubility is less than other sugars 
commonly used in food. Infant formula is a notable exception where the addition of lactose is necessary to 
match the composition of human milk. 
lactose is not fermented by yeast during brewing, which may be used to advantage.for example, lactose 
may be used to sweeten stout beer; the resulting beer is usually called a milk stout or a cream stout. 
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Another major use of lactose is in the pharmaceutical industry. lactose is added to pills as a filler because 
of its physical properties (i.e., compressibility) and low price. for similar reasons it can be used to dilute 
heroin. 
Polyvinylpyrrolidine [57] 
IUPAC name:poly[1-(2-oxo-1-pyrrolidinyl)ethylene]1-ethenyl-2-pyrrolidone homopolymer 1-vinyl-2-
pyrrolidone-polymere copovidone. 
Molecular formula: (C6H9NO)n 
Other  name             : povidone,polyvidone 
Density                     :1.2 g/cm3 
Appearance   : white to light yellow,hygroscopic. 
Melting point :  150-1800c 
 
 
Structural formula: 
 
Properties : 
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PVP is soluble in water and other polar solvents. When dry it is a light flaky powder, which readily absorbs 
up to 40% of its weight in atmospheric water. In solution, it has excellent wetting properties and readily 
forms films. This makes it good as a coating or an additive to coatings. 
Application: 
It is used as a binder in many pharmaceutical tablets;it simply passes through the body when taken orally. 
However, autopsies have found that crospovidone does contribute to pulmonary vascular injury in 
substance abusers who have injected pharmaceutical tablets intended for oral consumption.  The long-term 
effects of crospovidone within the lung are unknown. Pvp added to iodine forms a complex 
called povidone-iodine that possesses disinfectant properties.this complex is used in various products like 
solutions, ointment, pessaries, liquid soaps and surgical scrubs. It is known under the trade 
name betadine and pyodine. 
It is used in pleurodesis (fusion of the pleura because of incessant pleural effusions). For this purpose, 
povidone iodine is equally effective and safe astalc, and may be preferred because of easy availability and 
low cost. 
 
 
Safety: 
The U.S. Food and drug administration (fda) has approved this chemical for many uses,and it is generally 
considered safe. However, there have been documented cases of allergic reactions to pvp/povidone, 
particularly regarding subcutaneous (applied under the skin) use and situations where the pvp has come in 
contact with autologous serum (internal blood fluids) and mucous membranes. For example, a boy having 
an anaphylactic response after application of pvp-iodine for treatment of impetigo was found to 
be allergic to the pvp component of the solution.a woman, who had previously 
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experienced urticaria (hives) from various hair products, later found to contain pvp, had 
an anaphylactic response after povidone-iodine solution was applied internally. She was found to 
be allergic to pvp. In another case, a man experiencing anaphylaxis after 
taking acetaminophen tablets orally was found to be allergic to PVP 
Titanium-di-oxide [58] 
IUPAC name          :  titanium di oxide,titanium oxide. 
Molecular  formula  :  TiO2 
Other name                 : Titania.Rutile,Anatase. 
Appearance                 :  white solid. 
Melting point               :  18430c. 
Application: 
Titanium dioxide is the most widely used white pigment because of its brightness and very high refractive 
index, in which it is surpassed only by a few other materials. Approximately 4.6 million tons of pigmentary 
tio2 are consumed annually worldwide, and this number is expected to increase as consumption continues 
to rise. when deposited as a thin film, its refractive index and colour make it an excellent reflective optical 
coating for dielectric mirrors and some gemstones like "mystic fire topaz". Tio2 is also an 
effective opacifier in powder form, where it is employed as a pigment to provide whiteness and opacity to 
products such as paints, coatings, plastics, papers, inks, foods, medicines (i.e. Pills and tablets) as well as 
most toothpastes. In paint, it is often referred to offhandedly as "the perfect white", "the whitest white", or 
other similar terms. Opacity is improved by optimal sizing of the titanium dioxide particles. 
In ceramic glazes titanium dioxide acts as an opacifier and seeds crystal formation. 
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Titanium dioxide has been shown statistically to increase skimmed milk's whiteness, increasing skimmed 
milk's sensory acceptance score. 
Safety: 
Titanium dioxide is incompatible with strong reducing agents and strong acids. Violent or incandescent 
reactions occur with molten metal’s that are very electropositive, e.g. Aluminium, calcium, magnesium, 
potassium, sodium, zinc and lithium. 
Titanium dioxide accounts for 70% of the total production volume of pigments worldwide. It is widely 
used to provide whiteness and opacity to products such as paints, plastics, papers, inks, foods, and 
toothpastes. It is also used in cosmetic and skin care products, and it is present in almost every sunblock, 
where it helps protect the skin from ultraviolet light. 
Many sunscreens use nanoparticle titanium dioxide (along with nanoparticle zinc oxide) which, despite 
reports of potential health risks, is not actually absorbed through the skin. Other effects of titanium dioxide 
nanoparticles on human health are not well understood. Nevertheless, allergy to topical application has 
been confirmed. 
                                                   Iron oxide red [59] 
Molecular formula     : Fe2O3 
Other names                : Ferric oxide,Ferric iron,Red iron oxide . 
Appearance                  : Red brown solid 
Odour                             : odourless. 
Density                           : 5.242g/cm3 
Melting point                   : 15660c. 
Applications: 
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A very fine powder of ferric oxide is known as "jeweler's rouge", "red rouge", or simply rouge. It is used to 
put the final polish on metallic jewelry and lenses, and historically as a cosmetic.. Other polishing 
compounds are also often called "rouge", even when they do not contain iron oxide. Jewelers remove the 
residual rouge on jewelry by use of ultrasonic cleaning. Products sold asstropping compound are often 
applied to a leather strop to assist in getting a razor edge on knives, straight razors, or any other edged tool. 
 
Castor oil [60,61] 
Castor oil is a vegetable oil obtained from the castor bean (technically castor seed as the castor 
plant, Ricinus communis (Euphorbiaceae), is not a member of the bean family). The common name "castor 
oil" probably comes from its use as a replacement for castoreum, a perfume base made from the 
dried perineal glands of the beaver . 
Colour              : clourless to pale yellow liquid. 
Odour               : mild odor or odorless 
Taste                 : tasteless 
 Density            : 961 kg/m3 
Boiling point    : 313 °C 
Structural formula:  
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 Application: 
Castor oil used as a laxative with its major site of action the small intestine. Castor oil is a stimulant and 
lubricating laxative .It is not a preferred treatment, because it can produce painful cramps, fecal 
incontinence and explosive diarrhea. Its action can go on for hours, sometimes unpredictably and 
powerfully causing an involuntary bowel movement at inconvenient locations and during sleep.  
Undecylenic acid, a castor oil derivative, is also FDA-approved for over-the-counter use on skin disorders 
or skin problems. Castor isostearate succinate is a polymeric mixture of esters with isostearic 
acid and succinic acid used for skin conditioning, such as in shampoo, lipstick and lip balm. Ricinoleic 
acid is the main component of castor oil, and it exerts anti-inflammatory effects. It is believed that the 
antibacterial properties of the castor oil are mainly due to its high ricinoleic acid content.  
Therapeutically, modern drugs are rarely given in a pure chemical state, so most active ingredients are 
combined with excipients or additives. Castor oil, or a castor oil derivative such as Kolliphor 
EL (polyethoxylated castor oil, a nonionic surfactant), is added to many modern drugs, including: 
• Miconazole, an antifungal agent  
• Paclitaxel, a mitotic inhibitor used in cancer chemotherapy;  
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• Sandimmune (cyclosporine injection, USP), an immunosuppressant drug widely used in connection 
with organ transplant to reduce the activity of the patient's immune system;  
Isopropyl alcohol [62] 
Isopropyl alcohol is miscible in water, alcohol, ether and chloroform. It will dissolve ethyl cellulose, 
polyvinyl butyral, many oils, alkaloids, gums and natural resins. It is insoluble in salt solutions. 
Unlike ethanol or methanol, isopropyl alcohol can be separated from aqueous solutions by adding a salt 
such as sodium chloride, sodium sulfate, or any of several other inorganic salts, since the alcohol is much 
less soluble in saline solutions than in salt-free water. The process is colloquially called salting out, and 
causes concentrated isopropyl alcohol to separate into a distinct layer. 
IUPAC name           : propane-2-ol 
Structural formula :   
 
Other names                     :   2- propanol,isopropanol,isopropyl alcohol. 
Molecular formula          :   C3H8O 
Density                              :  0.786 g/cm3 
Appearance                      :  colourles solid 
Majority of isopropyl alcohol was used as a solvent for coatings or for industrial processes. Isopropyl 
alcohol in particular is popular for pharmaceutical applications, presumably due to the low toxicity of any 
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residues. Some isopropyl alcohol is used as a chemical intermediate. Isopropyl alcohol may be converted to 
acetone, but the cumene process is more significant. In that year, a tiny fraction (5.4 tonnes) was consumed 
for household use and in personal care products. It is also used as a gasoline additive 
Safety: 
Isopropyl alcohol vapor is denser than air and is flammable with a combustible range between 2 and 12.7% 
in air. It should be kept away from heat and open flame. Isopropyl alcohol has also been reported to 
form peroxides, which may explode upon concentration. Isopropyl alcohol is a skin irritant. 
 
 Methylene chloride [63] 
IUPAC names          : Dichloromethane. 
Other names            :  methylene chloride,methylene di chloride,narkotil,solaesthin. 
Structural formula :   
 
Density           :  1.33 g/cm3 
Appearance   : colourless liquid. 
Melting point  : -96.70c 
Taste                 : sweet aroma. 
Application: 
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DCM's volatility and ability to dissolve a wide range of organic compounds makes it a useful solvent for 
many chemical processes. Concerns about its health effects have led to a search for alternatives in many of 
these applications 
o Paint stripping 
o Pharmaceutical manufacturing 
o Metal cleaning and degreasing 
o Paint remover 
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MATERIAL AND METHODS: 
List of materials used 
 
Table:12 
 
S.no Materials Source 
1 Valsartan Paxmy speciality chemicals, 
Mumbai 
2 Microcrystalline cellulose Welming chemicals, india 
3 Lactose S.d.fine-chem.,pvt ltd 
4 Crospovidone Nanhany  industrial &co, 
china 
5 Polyvinyl pyrrolidine Welming chemicals,india 
6 Colloidal silicon dioxide Amaratal &co.,cennai 
7 Mannitol S.d.fine-chem.,pvt ltd 
Mumbai 
8 Magnesium stearate Loba chemie.,pvt ltd, 
Mumbai 
9 Talc Loba chemie,.pvt ltd 
Mumbai 
10 Crosscarmellose S.d. Fine-chemi., pvt ltd 
Mumbai 
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List of materials used for film coating 
 
Table: 13 
s.no Materials Source 
1 Hydroxyl propyl methyl cellulose Loba chemie., pvt ltd,. 
Mumbai 
2 Titanium di oxide amaratal&co., 
chennai 
3 Castor oil Tablets pvt ltd., 
chennai 
4 Iron oxide red Signet chemical ., 
Chennai 
5 Iso propyl alcohol Loba chemie.,pvt ltd,. 
Mumbai 
6 Methylene chloride Paxmy speciality 
chemicals., 
mumbai 
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                                                  List of equipments used 
 
Table:14 
 
S.no 
 
Equipment 
 
company 
1 Electronic balance Melter Toledo,Mumbai 
2 Bulk density apparatus Electrolab,mumbai 
3 Double cone blender Erweka 
4 Rotary tablet punching machine Rimek., chennai 
5 Friability test apparatus Electrolab., Mumbai 
6 Tablet hardness tester Schleuniger hardness tester., 
7 Digital vernier caliper Mitutiyo.,japan 
8 Stability chamber Servewell instruments pvt ltd.,banglore 
9 UV-visible spectrophotometer Shimadzu corporation.,japan 
10 FTIR Shimadzu corporation.,japan 
11 HPLC Shimadzu coporation., japan 
12 USP dissolution apparatus Electrolab.,mumbai 
 
 
 
 
 
 
 
 
 
Page | 100  
 
Experimental investigation 
Market sample details 
Product name                             : Diovan-80mg 
Label claim                                : Each tablet contain 80mg of valsartan 
Manufactured by                      : Novartis pharmaceuticals Pvt ltd . 
Description                               : Pale pink in colour, round flat shaped concave, film coated tablet 
 Thickness                                  : 4.23mm 
Storage                                      : Store at 25 °c, protect from light and    
Dissolution apparatus              : Paddle type (USP apparatus) 
Dissolution medium                 : Phosphate buffer solution ph-6.8bufer. 
Dissolution medium volume   : 900 ml 
Time points                               : 10, 20, 30, 45minutes 
Speed                                         : 50 rpm 
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Active Pharmaceutical Ingredient characterization [64]: 
Physical appearance:  
The Valsartan powder was examined for its organoleptic properties like colour and odour. 
Valsartan   is white or off  white crystalline powder and it is found odour less. 
Bulk density:   
Active pharmaceutical ingredient valsartan sample powder was introduced in 100 ml graduated cylinder. 
The volume of the material was noted on graduated cylinder. The bulk density was calculated by the 
formula given below 
 Bulk density (ρ0) = M/Vo 
   
Where, M = mass of the powder  
 Vo = volume of the powder   
Tapped Density:  
 The valsartan sample was screened through sieve no. 18 and the weight of sample equivalent to 
10 g was filled in 100 ml graduated cylinder. The mechanical tapping of the cylinder was carried out at a 
rate of 300 drops per minute for 500 times from 3” height and the tapped volume Vf was noted. The tapped 
density was calculated in gm/ cm3 by the formula, 
Tapped density (ρt) = M/Vf 
Where, M = weight of sample powder taken 
Vf = tapped volume 
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Hausner Ratio: 
It indicates the flow properties of the powder and is measured by the ratio of tapped density to bulk density. 
 Hausner Ratio = Tapped density / Bulk density 
 Compressibility index (Carr’s index): 
Compressibility index is an important measure that can be obtained from the bulk and tapped densities. In 
theory, the less compressible a material the more flow able it is. A material having values of less than 20 to 
30% is defined as the free flowing material.  
 Compressibility index = 100 (V0 – Vf )         
                                            V0  
                            Table No: 15 Compressibility index specifications 
% Comp. Index Properties 
5-12 Free flowing 
12-16 Good 
18-21 Fair 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
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Solubility study:  
The valsartan sample was qualitatively tested for its solubility in various solvents. It was determined by 
taking 10 mg of   valsartan drug sample in 10 ml of solvent as water, methanol, ethanol, acetonitrile, pH 
buffer 6.8 in small test tubes and well solubilized by shaking.  
                          Table-16  Solubility of valsartan: 
S.no Solvent Solubility 
1 Phosphate buffer 6.8 Soluble 
2 Methanol Freely Soluble 
3 Ethanol Freely soluble 
4. Acetonitrile Soluble 
 
Melting point determination:  
The Melting point was determined by the capillary method using Digital Melting point apparatus. The 
capillary tube was fused and filled by pressing the open end gently into pure drug sample and packed by 
tapping the bottom of the capillary on a hard surface so that the drug packed down into the bottom of the 
tube. When the drug was packed into the bottom of the tube, the  tube was placed into the slot of the 
apparatus, the apparatus was started and the temperature was noted at which the drug melt. 
Meting point of valsartan found to be 116°C. 
Calibration  for pure drug valsartan: 
Preparation of standard stock solution:  
    Standard drug solution of valsartan was prepared by dissolving 50mg pure valsartan in methanol and 
transferred into 100ml volumetric flask to obtain 500μg/ml of stock solution from which desired 
concentrations of solutions were prepared. 
Preparation of test solution:  
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      10 Tablets were weighed and its average weight was determined. An accurately weighed tablet power 
equivalent to 25 mg of valsartan transferred into 50 ml volumetric flask dissolved in 25 ml of methanol and 
sonicated for 10 min and volume was made upto the mark and solution was filtered using whattman filter 
paper to obtain 500μg/ml stock solution .  
Determination of λ max:  
      10 μg/ml solution of valsartan was prepared and scanned in UV range of 200-400nm and spectrum was 
obtained. The λ max was found to be at 250nm wave length where absorbance was maximum at this 
wavelength. Hence this is considered as absorbance maxima (λ max) shown in fig-2 
 Fig-2  λ max of valsartan: 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of calibration curve:  
       Standard stock solution was suitably diluted with methanol to obtain concentrations ranging from 2-20 
μg/ml. Absorbance of these solutions was measured at 250nm (λ max valsartan) using UV, calibration 
curve was obtained by plotting graph between concentration and absorbance shown in fig-3 
Linearity:  
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        Linearity was obtained between2-20μg/ml concentration. Graph was plotted for concentration and 
absorbance. The equation of calibration curve obtained was Y=0.028x+0.00. The correlation coefficient 
(R²) was 0.998 shown in fig-3 
Calibration of valsratan in methanol at250nm 
Table:17 
S.no Concentration(μ g/ml ) Absorbance 
1 5 0.121 
2 10 0.286 
3 15 0.422 
4 20 0.591 
5 25 0.696 
6 30 0.849 
7 35 1.022 
8 40 1.128 
9 45 1.291 
10 50 1.389 
 
Fig-3 Calibration of valsartan: 
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Calibration curve of valsartan
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 Preformulation 
Compatibility Studies between drug and excipients : 
Fourier Transform Infrared Spectrophotometry (FTIR): 
       Compatibility study of valsartan with the excipients was determined by I.R. Spectroscopy (FTIR) 
using Perkin Elmer spectrum RX1 FT-IR spectrometer model. The pellets were prepared at high 
compaction pressure by using potassium bromide and the ratio of sample to potassium bromide is 
1:100.The pellets thus prepared were examined and the spectra of valsartan and other ingredients in the 
formulations were recorded in the region of 4000 to 400cm⁻¹. compared with that of the original spectra of 
valsartan . 
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TABLE: 18. Composition of valsartan tablets 
 
INGREDIENTS F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
F8* 
(mg) 
 
Valsartan 
 
80 
 
80 
 
80 
 
80 
 
80 
 
80 
 
80 
 
80 
 
Microcrystalline 
Cellulose 
 
90 
 
 
 
88 
 
88 
 
85 
 
88 
 
90 
 
85 
 
85 
 
Lactose 
 
70 
 
70 
 
67 
 
65 
 
70 
 
65 
 
65 
 
65 
 
Mannitol 
 
20 
 
20 
 
 
20 
 
 
20 
 
 
20 
 
20 
 
20 
 
20 
 
Poly vinyl 
pyrrolidine 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
Cross povidone 
 
- 
 
2 
 
5 
 
10 
 
- 
- 
 
 
- 
 
5 
 
Colloidal silicon dioxide 
 
4 
 
 
4 
 
4 
 
4 
 
4 
 
4 
 
4 
 
4 
 
Magnesium stearate 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
Talc 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
Crosscarmellose 
 
 
_ 
 
- 
 
- 
 
- 
 
 
2 
 
5 
 
10 
 
5 
 
Total(mg) 
 
275 
mg 
 
275 
mg 
 
275 mg 
 
275 mg 
 
275 mg 
 
275 mg 
 
275 mg 
 
275 mg 
 
F8*-optimized formulation 
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 Table:19, composition of coating valsartan  
 
S. no 
 
Coating ingredients 
 
Weight 
For 1000 
tablets 
 
1. 
 
 
Hydroxy  propyl methyl 
cellulose 
 
5gm 
 
2. 
 
Titanium di oxide 
 
1gm 
 
3. 
 
Castor oil 
1gm 
 
4. 
 
 
Iron oxide red 
 
 
1gm 
 
5. 
 
Iso propyl alcohol 
 
100ml 
 
6. 
 
Methylene chloride 
 
150ml 
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2. Preparation of powder blend: 
Dispensing of materials 
 All the solid raw materials are dispensed and packed in a individual clean Poly bags and label.  
Sifting 
     Separately valsaratan drug, micrcrystallinecellulose, crosspovidone,mannitol,lactose,colloidal silicon 
dioxide, polyvinyl pyrrolidine are all passed through 40# mesh and  magnesium stearate and talc passed 
through 60#mesh 
Collect all the  above  sifted materials individually into a double lined poly ethylene bag. 
Mixing 
   Load sifted valsartan drugs, mannitol, microcrystalline cellulose,lactose, polyvinylpyrrolidine, colloidal 
silicon dioxide, , crospovidone,  crosscarmellose into blender and mix for 10 mnutes. 
 
Lubrication 
  Lubricate the above blend with magnesium stearate and talc blend for 3-5minutes. 
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 Evaluation of Blend characteristics : 
Bulk density: 
 Bleneded  drug and excipients sample powder has to be introduced in 100 ml graduated cylinder. The 
volume of the material was noted on graduated cylinder. The bulk density was calculated by the formula 
given below; 
 Bulk density (ρ0) = M/Vo 
Where, M = mass of the powder  
 Vo = volume of the powder  
Tapped Density:  
 Blended drug and excipients  powder sample has to be screened through sieve no. 18 and the 
weight of sample equivalent to 10 g was filled in 100 ml graduated cylinder. The mechanical tapping of the 
cylinder was carried out at a rate of 300 drops per minute for 500 times from 3” height and the tapped 
volume Vf was noted.  
The tapped density was calculated in gm/ cm3 by the formula, 
Tapped density (ρt) = M/Vf 
Where, M = weight of sample powder taken 
Vf = tapped volume 
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  Hausner’s Ratio 
     It indicates the flow properties of the powder and is measured by the ratio of tapped density to the bulk 
density.  
Hausner’s Ratio = Tapped density/Bulk density 
Compressibility index (Carr’s indices) 
 Compressibility index is an important measure that can be obtained from the bulk and tapped 
densities. In theory, the less compressible a material the more flowable it is. A material having values of 
less than 20 to 30% is defined as the free flowing material.  
 
   CI   = 100 (VO – Vf) 
                          V0 
Angle of repose: 
For determination of angle of repose , the drug and the blend were poured through the walls of a 
funnel, which was fixed at a position such that its lower tip was at a height of exactly 2.0 cm above hard 
surface. The drug and the blends were poured till the time when upper tip of the pile surface touched the 
lower tip of the funnel. 
Angle of repose was calculated using following equation. 
 
Angle of Repose (θ) = tan-1(h/r). 
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Preparation of tablets: 
 
Fig-4, flow chart for preparation of uncoated tablets 
 
 
Dispensing of materials: All the solid raw materials are dispensed 
 
 
Valsaratan,micrcrystallinecellulose,crosspovidone,mannitol,lactose,colloidal 
silicon dioxide, poly vinyl pyrrolidine are all passed through 40# mesh and  
magnesium stearate ,and talc passed through 60#mesh 
 
 
API  and  other excipients are mixed in blender for 10 minute 
 
Lubricate the above blend with magnesium stearate ,talc in the blender 
 
Compression: Compress the lubricated blend as per the specification  
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 Evaluation of Uncoated tablets: 
Physical appearance:          
              The general appearance of the valsartan uncoated tablet ,its identity and general elegance is 
essential for consumer acceptance,for control of lot-to- lot uniformity and tablet to tablet uniformity.the 
control of general appearance involves the measurement as follows           
Size and Shape      - Round flat faced concave shape  
Colour                    - white 
Odour                     - odour less 
taste                        - tasteless 
Weight variation test: 
      Twenty (20) valsartan uncoated tablets from each batch were individually weighed. The average 
weight and standard deviation were calculated, individual weight of each tablet was also calculated using 
the same and compared with average weight 
Weight Variation limits as per USP and the values were showed in the table-6 
The content uniformity approach is preferred over the weight variation approach as it more precisely 
reflects the variation of the active ingredient from tablet to tablet. 
The required specification for this test is that uniformity of dosage unit should be within a range of 85%–
115% with a relative standard deviation of less than or equal to 6%. 
Friability: 
A  sample of valsartan uncoated 10 tablets are tested at a time, unless tablet weight is 0.65 g or less, 
where 20 tablets are tested. After 100 turns, the tablet samples are evaluated by weighing. If the 
reduction in the total mass of the tablets is more than 1%, the tablets fail the friability test.  
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Thickness: 
    The thickness in millimeters (mm) was measured individually for 10 pre weighed tablets by using a 
Vernier Caliper’s.  
Hardness testing: 
 
      The most widely used apparatus to measure tablet hardness is the Schleuniger apparatus.  
 Generally, the force required to break a valsartan uncoated tablet may be expressed in either kilograms or 
pounds.  
Disintegration test: 
         The apparatus employs a basket of six tubes with a base of metal sieve. A valsartan uncoated tablet is 
placed in each tube and is held in place by a plastic weight. The six-tube assembly, containing six  
valsartan tablets, is suspended using a hanger with a mechanism of vertical motion at a fixed speed of 28- 
32 cycles/minute. While hanging the six-tube assembly on the hanger, the assembly is moved in vertical 
motion in water or a buffer solution. The time for disintegration of each tablet is recorded and should meet 
the required time specification 
 
Assay of valartan [11]: 
       The valsartan content in each tablet is assayed by HPLC method using X-terra RP-18 column(100 
x4.6mm,5µm)by injecting20µL of sample with a flow rate of 2.0mL/min and a run time of 15min at an 
ambient temperature using a uv detector at273 nm 
Preparations: 
Mobile phase preparation : 
A mixture of 50volumes of water,50 volumes of acetonitrile and 0.1volume of glacial acetic acid. 
 
Reference solution: 
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0.005% w/v solution of valsartan RS in mobile phase. 
Test solution preparation: 
Weigh and powder 20tablets.weigh accurately a quantity of powder containing 50mg of valsartan, 
disperse in 25ml of mobile phase and dilute to 100ml with Mobile phase and filter. dilute 5.0ml of this 
solution  to 50ml with the mobile phase. 
Chromatographic system: 
A stainless steel column 25cm x 4.6mm, packed with octadecylsilane bonded to porous silica(5µm). 
Flow rate .1ml per minute, spectrophotometer set at 273nm,injection volume.10µl.Inject the reference 
solution .the test is not valid unless the tailing factor is not more than2.0 and the relative standard 
deviation for replicate injections is not more than 2.0percent.inject the test solution and reference solution. 
Calculate the content of valsartan in tablets. 
System suitability: 
              Chromatograph standard preparations (five relicate injection )measure the peak area responses for 
the analyte peak evaluate the system suitability parameters as directed. 
Acceptance criteria: 
%RSD for replicate injection of peak area response of the valsartan peak from the standard preparation 
should not be more than 2.06 
The tailing factor for valsartan peak should be not more than 2.0 
The number of theoretical plate for valsartan peak should not be less than 2000 
 
 
Assay formula: 
Sample area    x    std. weight       x     1     x    100       x          50     x     std. purity       x    275.9 
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Std. area                    50                 100      spl.weight       5                10 
Preparation of coating tablets: 
Fig :5 flow chart for  preparation of coating tablets 
Coating material dispensed and collected in separated poly bags. 
 
         
 
 
HPMC added to one part of 
isopropylalcohol.  
 Iron oxide red, titanium oxide was added to 
other part of isopropyl alcohol. 
 
Stir for 5-10minutes. 
 
Castor oil added and passed through 
colloidal mill.mix it with above solution. 
 
Methylene chloride added by continuos 
stirring of coating solution. 
 
Above solution has to been filtered through 
100#mesh nylon cloth. 
 
Above solution is coated to the tablet 
through pan using spray gun.  
 
Isopropyl alcohol was transferred to steel vessel. 
Stirr for 10 minutes. 
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 Evaluation of Coated tablets: 
Physical appearance: 
      The general appearance of the valsartan coated tablet,its identity and general elegance is essential for 
consumer acceptance, for control of lot-to- lot uniformity and tablet to tablet uniformity. the control of 
general appearance involves the measurement as follows           
Colour    -pale  reddish in colour 
Odour     -odourless 
Taste        -tasteless 
Friability: 
A  sample of valsartan coated 10 tablets are tested at a time, unless tablet weight is 0.65 g or less, 
where 20 tablets are tested. After 100 turns, the tablet samples are evaluated by weighing. If the reduction 
in the total mass of the tablets is more than 1%, the tablets fail the friability test.  
No cracked, cleaved, or broken tablets are seen. 
Thickness: 
       The thickness in millimeters (mm) was measured individually for 10 pre weighed tablets by using a 
Vernier Caliper’s. The average thickness and standard deviation were reported in table- 
 Hardness testing: 
        The most widely used apparatus to measure tablet hardness is the Schleuniger apparatus.  
 Generally, the force required to break a valsartan coated tablet may be expressed in either kilograms or 
pounds 
Disintegration test: 
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       The apparatus employs a basket of six tubes with a base of metal sieve. A valsartan tablet is placed in 
each tube and is held in place by a plastic weight. The six-tube assembly, containing six tablets, is 
suspended using a hanger with a mechanism of vertical motion at a fixed speed of 28- 32 cycles/minute. 
While hanging the six-tube assembly on the hanger, the assembly is moved in vertical motion in water or a 
buffer solution. The time for disintegration of each tablet is recorded and should meet the required time 
specification 
Dissolution of valsartan tablets 
Apparatus: 
The paddle method (USP Apparatus 2)  
Dissolution medium: 
            Dissolution testing should be carried out under physiological conditions, if possible. This allows 
interpretation of dissolution data with regard to in-vivo performance of the product. However, strict 
adherence to the gastrointestinal environment need not be used in routine dissolution testing. The testing 
conditions should be based on physicochemical characteristics of the drug substance and the 
environmental conditions the dosage form might be exposed to after oral administration 
              To simulate intestinal fluid (SIF), a dissolution medium of pH 6.8 should be employed. A higher pH 
should be justified on a case-by-case basis and, in general, should not exceed pH 8.0.  
Standard solution: 
50 mg of valsartan drug has been taken and made uto 100 ml with methanol then pipette out 2ml from 
above solution and make upto 100ml with phosphate buffer pH6.8. 
Buffer preparation: 
pH-6.8 phosphate buffer is prepared by taking 40.8 gm of potassium dihydrogen phosphate. and 
5.376gm of sodium hydroxide was added and made upto 6000ml with water. 
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Sample preparation: 
1.Transfer 900 ml of dissolution media into each dissolution vessel. 
2.Weigh six tablets randomly chosen and transfer one tablet into the each dissolution vessel. 
3.Withdraw suitable volume of sample from the solution from the above vessel at the sampling time 
pointsrespectively.  
4. Replace aliquots withdrawn for analysis with equal volumes of dissolution medium which is maintained 
at 37.0 ± 0.5°C. 
Formula for dissolution: 
sample .absorbence  x     std.weight    x        2   x         900       x           10     x    98.81(std.purity)   
                                                                                                            
Std. absorbence                100                    100             1                     1            100    
    
In vitro dissoluton studies: 
The dissolution conditions   used for invitro drug release. 
APPARATUS                   : USP  apparatus II (paddle) 
AGITATION SPEED       : 50 rpm 
MEDIUM                          : 37.0 ± 0.5°C 6.8 phosphate buffer 
VOLUME                          : 900 ml 
TEMPERATURE              : 37.0 ± 0.5°C 
TIME                                  :10min, 20min,30min,and 45min 
 
Stability data: 
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The optimized tablets from batch f 7 were charged for stability studies at 400c and 75%rh.there was no change 
in physical appearance , colour. Optimized formulation were analyzed at the end of 3 months for general 
tablet properties like hardness, friability, disintegration and dissolution studies. Tables have shown that there 
is no much deviation in friability and hardness values. And in vitro dissolution profile showed that there was 
no significant change in the release rate of the drug from optimized tablet at the end of 3months. 
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RESULT AND DISCUSSION: 
 Table-20 Active Pharmaceutical Ingredient Characterization: 
Ingredient Buk 
density(gm/cm3) 
Tapped 
density(gm/cm3) 
Angle 
of 
repose 
Compressibilit
y index% 
Hausner’s 
ratio 
Valsartan 0.31 0.34 19.2 8.82% 1.09 
 
Inference: Result indicates  bulk density, tapped density , angle of repose, compressibility index, hausner’s 
ratio for API is found within the limits. 
Preformulation studies: 
Compatibility Studies between drug and excipients: 
Fig-6 FTIR spectrum  of  valsartan
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Fig-7 FTIR spectrum  of valsartan & excipients 
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Table: 21 Interpretation of FTIR spectrum of valsartan (fig-6) 
S.NO WAVENUMBER(cm⁻¹) VIBRATIONS 
1. 3448.1 CH- stretching (aliphatic) 
2. 2964.2 Aromatic.CH- streching 
3. 759.5 Aromatic.CH-bending 
4. 1426.1 N=N. streching 
5. 1735.0 C=O. stretching (ke stretching(ketone) 
6. 1274.2 O-H bending(aromatic) 
 
Table: 22 Interpretation of FTIR spectrum of valsartan & excipients (fig-7) 
S.NO WAVENUMBER(cm⁻¹) VIBRATIONS 
1. 3400.30 CH- stretching (aliphatic) 
2. 2963.1 CH- stretching (aromatic) 
3. 778.0 CH-bending(aromatic) 
4. 1438.5 N=N  streching 
5. 1725.6 C=O stretching (ketone) 
6. 1281.4 O-H bending (alcohol) 
     
Inference: Results indicates that there is no extra peak found in the  sample (drug and  excipients ) when 
compared with pure drug spectrum. 
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Evaluation of Blends: 
Table: 23 
 
S.No 
 
Formulatio
ns 
 
Bulk 
Density 
(g/ml) 
 
Tapped 
Density 
(g/ml) 
 
Angle of 
repose 
 
Compressibility 
Index(%) 
 
Hausners 
ratio 
1. F-1 0.482 0.576 33.4 15.78 1.19 
2. F-2 0.357 0.419 31.6 14.63 1.11 
3. F-3 0.605 0.710 29.3 15.49 1.18 
4. F-4 0.584 0.685 31.9 14.71 1.17 
5. F-5 0.354 0.418 32.1 14.63 1.16 
6. F-6 0.434 0.507 30.5 13.66 1.15 
8. F-7 0.452 0.527 31.5 14.25 1.16 
7. F-8 0.465 0.538 29.1 13.52 1.15 
 
Inference: Result indicates that Bulk density, tapped density , angle of repose, compressibility index,  
hausner’s ratio of powder blend is found within the limits. 
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Evaluation of uncoated tablets: 
Table-24 physiochemical properties of uncoated tablet 
 
S.No 
 
Formulations 
 
Thickness 
(mm)  
 
Hardness 
Kg/cm2    
 
Disintegration 
Time(mins) 
 
Friability 
  (%)  
 
Assay 
% 
1. F-1 4.18 7.8 13min 12 sec 0.14 93.2 
2. F-2 4.15 6.2 8 min 40 sec 0.12 93.6 
3. F-3 4.13 7.5 7 min 17 sec 0.16 98.2 
4. F-4 4.21 5.5 4 min 52 sec  0.08 96.5 
5. F- 5 4.16 6.0 7 min25 sec 0.18 94.8 
6. F-6 4.22 5.4  5 min 56sec 0.09 97.1 
7. F-7 4.19 4.5  3 min 23 sec 0.15 98.8 
8. F-8 4.32 4.6  2 min32 sec 0.12 96.9 
 
Table-25, Weight variation: 
 F1 F2 F3 F4 F5 F6 F7 F8 
AVG 
WT(20 
TAB) 
275.35 270.49 278.87 268.06 283.80 272.15 277.82 275.66 
% max 
positive 
deviation 
+2.89 +1.98 +2.5 +1.62 +2.42 +2.63 +1.98 +2.14 
% min 
negative 
deviation 
-2.13 -2.56 -1.89 -1.56 -2.63 -2.96 -1.68 -2.21 
Inference: Result Indicates thickness,  hardness,  friability,  disintegration,   weight variation , assay are  
within the pharmacopeial limits. 
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Evaluation of Film Coated Tablets: 
Table:26 phsiochemical properties of film coated tablets. 
 
S.No 
 
Formulations 
 
Thickness 
(mm)  
 
Hardness 
Kg/cm2    
 
Disintegration 
Time(mins) 
 
Friability 
  (%)  
 
Assay 
% 
1. F-1 4.28 7.8 13 min 42 sec 0.14 93.2 
2. F-2 4.21 6.5 10 min 58sec 0.10 93.6 
3. F-3 4.24 7.5 8  min 37 sec 0.16 98.4 
4. F-4 4.40 5.8 7 min 8 sec  0.08 96.5 
5. F- 5 4.23 6.0 9 min47 sec 0.18 94.8 
6. F-6 4.42 5.4 8  min 15 sec 0.09 97.1 
7. F-7 4.25 4.5 5 min 28 sec 0.15 98.7 
8. F-8 4.32 4.8 2 min 41 sec 0.15 96.9 
9. Marketed 
product 
4.23 4.7 3 min  12sec 0.12 94.4 
 
Inference: Result   indicates thickness, hardness, friability, disintegration , assay of valsartan tablet is 
found to be within the limit. 
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Assay: typical chromatogram of valsartan  
1.Fig-8 chromatogram of pure valsartan drug  
 
2. Fig-9 chromatogram of sample valsartan: 
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 In-vitro dissolution studies: 
The dissolution conditions   used for in vitro drug release .. 
APPARATUS                   : USP apparatus II (paddle type ) 
AGITATION SPEED       : 50 rpm 
MEDIUM                          : pH 6.8 phosphate buffer 
VOLUME                          : 900ml 
TEMPERATURE              : 37.0 ± 0.5°C 
TIME                                  : 10min, 20min, 30min and 45min 
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Results of dissolution profile: 
Table: 27 Invitro dissolution profile of all the formulation 
            
 Inference: Result indicates formulation 8 showed good drug release profile. when compared with the marketed   
product . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No 
 
Time 
(min) 
 
F1 % 
 
F2 % 
 
 
F3 % 
 
 
F4 % 
 
 
F5 % 
 
 
F6 % 
 
F7 % 
 
 
F8 % 
 
Market 
Sample 
1. 10 32.18 48.28 52.5 65.72 53.03 61.53 70.23 76.62 72.12 
2. 20 48.32 61.67 69.92 76.83 68.46 74.15 81.66 84.03 80.96 
3. 30 59.51 72.14 79.64 84.36 76.22 82.41 86.77 90.56 86.74 
4. 45 68.77 80.50 83.98 86.6 82.87 86.26 88.43 96.74 90.56 
Page | 130  
 
 
 
Invitro dissolution studies: 
Fig-10 Invitro dissolution profile of formulation (F1): 
 
Fig-11, Invitro dissolution profile of formulation ( F2-F4) 
. 
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Fig-12 Invitro dissolution profile of formulation (F5-F7) 
 
Fig-13 Invitro dissolution profile of formulation ( F8) 
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Fig-14 Invitro dissolution profile comparison between formulation (F8)  
and marketed product 
 
 
Inference: 
• Invitro dissolution release of all the formulation were showed in fig:10-14  
• The formulation 8 showed best fit of dissolution profile when compared with marketed product. 
• Formulation 1,showed very low drug release due to absence of disintegrant in the formulation. 
• The drug release was increased in formulation F2, F3, F4 due to addition of superdisintegrant 
crospovidone in the formulation. But the release profile was not matched with marketed product . 
• The drug  release was increased in the formulation F5, F6, F7 due to addition of superdisintegrant  
crosscarmellose in the formulation .but the drug release was not fit with marketed product. 
• So the formulation F8 consist of  combination of  superdisintegrant  crospovidone and 
croscarmellose , showed best match release profile with marketed product.The result attributed that 
, they wetting and swelling property was significantly increased in combination of super 
disintegration. 
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Stability studies: 
Table: 28 Accelerated stability studies for 3 months: 400c and 75%RH 
 
Characteristics 
 
Initial 
 
1stmonth 
 
2ndmonth 
 
3rdmonth 
 
Hardness 
 
4.6 
 
4.6 
 
4.6 
 
4.6 
 
%friability 
 
0.15 
 
0.15 
 
0.15 
 
0.15 
 
Disintegration 
 
2min32 sec 
 
2 min 37sec 
 
2min  41sec 
 
2 min 4 sec 
Assay 
(LIMIT-90-110%) 
 
98.8% 
 
96.5% 
 
 
95.9% 
 
93.2% 
 Dissolution(NLT 
70%) 
 
96.23% 
 
94.68% 
 
93.93% 
 
93.21% 
Moisture content 
(NMT-5.0%) 
 
1.826% 
 
1.953% 
 
1.987% 
 
2.028% 
Description (pale 
reddish colour,round 
shaped concave film 
coated tablet) 
 
 
Comply 
 
Comply 
 
Comply 
 
Comply 
Inference: Stability studies for the optimized tablets were carried out at 400C+20C, 75%+5%RH    for a 
period of three  months .Tablets were evaluated for physical appearance , colour,  hardness, friability, 
disintegration and dissolution studies. Tablets have not shown any significant changes  during the study 
period . 
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Conclusion: 
The valsartan film coated tablets have been developed with direct compression method and it was 
compared with that of marketed product. The powder blend were subject to various physical characteristics 
tests such as bulk density, tapped density, Hausners ratio, compressibility index and core tablets were 
evaluated for weight variation, hardness, thickness, disintegration time and the results were within 
specification. In-vitro dissolution profile of developed formula was compared with marketed product and 
drug  release profile of formula 8 was found to be matched with  marketed product. The combination of 
superdisintegrants, crosscarmellose and cropovidone was shown faster disintegration rate. The optimized 
batch tablets were packed in HDPE bottle and performed stability studies at 40°C/75%RH. Stability 
samples were evaluated initially and upto three months. All the results were found to be satisfactory. Hence 
the designed and developed formula was stable. Valsartan film coated tablet developed in the present work 
was found to be pharmaceutically equivalent to marketed product. 
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